WO2021147993A1 - 抗trop-2抗体-依喜替康类似物偶联物及其医药用途 - Google Patents

抗trop-2抗体-依喜替康类似物偶联物及其医药用途 Download PDF

Info

Publication number
WO2021147993A1
WO2021147993A1 PCT/CN2021/073279 CN2021073279W WO2021147993A1 WO 2021147993 A1 WO2021147993 A1 WO 2021147993A1 CN 2021073279 W CN2021073279 W CN 2021073279W WO 2021147993 A1 WO2021147993 A1 WO 2021147993A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
trop
seq
cancer
variable region
Prior art date
Application number
PCT/CN2021/073279
Other languages
English (en)
French (fr)
Inventor
杨阳
胡齐悦
陶维康
Original Assignee
江苏恒瑞医药股份有限公司
上海恒瑞医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司, 上海恒瑞医药有限公司 filed Critical 江苏恒瑞医药股份有限公司
Priority to AU2021210074A priority Critical patent/AU2021210074A1/en
Priority to EP21744789.5A priority patent/EP4095148A4/en
Priority to CN202180007477.0A priority patent/CN114846021A/zh
Priority to KR1020227026893A priority patent/KR20220130717A/ko
Priority to JP2022543188A priority patent/JP2023510905A/ja
Priority to CA3168260A priority patent/CA3168260A1/en
Priority to MX2022008474A priority patent/MX2022008474A/es
Priority to US17/793,005 priority patent/US20230101735A1/en
Priority to BR112022014189A priority patent/BR112022014189A2/pt
Publication of WO2021147993A1 publication Critical patent/WO2021147993A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present disclosure relates to an anti-TROP-2 antibody, an anti-TROP-2 antibody-Isinotecan analog conjugate, a preparation method thereof, a pharmaceutical composition containing the same, and its use in the preparation and treatment of TROP-2 mediated diseases or Use in medicines for diseases; especially in the preparation of anti-cancer drugs.
  • TROP-2 is human trophoblast cell surface glycoprotein antigen 2, also known as tumor-associated calcium signal transducer 2 (TACSTD2), epidermal glycoprotein 1 (EGP-1), gastrointestinal tumor-associated antigen (GA733-1), Surface marker 1 (M1S1) is a cell surface glycoprotein encoded and expressed by the Tacstd2 gene in the 1p32 region of chromosome.
  • TROP-2 belongs to the GA733 protein family, and has a high structural sequence similarity with epithelial cell adhesion molecules (EpCAM, also known as Trop1, TACSTD1), with a homology of 49%.
  • EpCAM epithelial cell adhesion molecules
  • TROP-2 protein The primary structure of TROP-2 protein is a 36kD polypeptide composed of about 323 amino acids.
  • the primary structure is post-translationally modified by N-terminal glycosylation to form a type I cell membrane glycoprotein that is different from EpCAM, namely TROP-2 protein.
  • TROP-2 protein spans the cell membrane, and the N-terminal is the extracellular domain (Trop2EC).
  • the extracellular domain passes through a unidirectional transmembrane helix (TM) and a short intracellular tail of a hydrophobic polypeptide composed of 26 amino acid residues (Trop2IC). ) Connect to fix to the cell membrane.
  • TROP-2 is of great significance in the process of embryonic development and tumor cell proliferation and metastasis.
  • TROP-2 was originally found in trophoblast cells and used as a surface marker. Trophoblast cells originate from the extraembryonic trophoblast. TROP-2 helps embryo implantation and placental tissue formation, and is useful in maintaining embryonic stem cell proliferation and organ formation. Play an important role in the development process.
  • TROP-2 is also an important tumor development-related factor. It is highly expressed in a variety of tumors, such as pancreatic cancer, breast cancer, colon cancer, gastric cancer, oral squamous cell carcinoma, ovarian cancer, etc. It can promote tumor cell proliferation, In the process of invasion, metastasis and spread, its high expression is closely related to the shortened survival and poor prognosis of tumor subjects. Therefore, the research of anti-tumor drugs targeting TROP-2 is of great significance.
  • Antibody-drug conjugate connects monoclonal antibodies or antibody fragments with biologically active cytotoxins through linker compounds, making full use of the specificity and cellular binding of antibodies to normal cells and tumor cell surface antigens.
  • ADC Antibody-drug conjugate
  • the present disclosure relates to anti-TROP-2 antibodies, ADCs and uses thereof, and provides ADC drugs coupled with anti-TROP-2 antibodies or antigen-binding fragments and cytotoxic substance exenotecan analogs.
  • the present disclosure provides a ligand-drug conjugate represented by the general formula (Pc-L-Y-D) or a pharmaceutically acceptable salt thereof:
  • Y is selected from -O-(CR a R b ) m -CR 1 R 2 -C(O)-, -O-CR 1 R 2 -(CR a R b ) m -, -O-CR 1 R 2- , -NH-(CR a R b ) m -CR 1 R 2 -C(O)- and -S-(CR a R b ) m -CR 1 R 2 -C(O)-;
  • R a and R b are the same or different, and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxyalkyl group group, cycloalkyl group and heterocyclic group; form a cycloalkyl or heterocyclic group, or, R a and R b are carbon atoms connected thereto;
  • R 1 is selected from halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclic group, aryl and heteroaryl;
  • R 2 is selected from hydrogen atom, halogen, Haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl and heteroaryl; alternatively, R 1 and R 2 form together with the carbon atom to which they are attached Cycloalkyl or heterocyclic group;
  • R a and R 2 together with the carbon atom to which they are connected form a cycloalkyl group or a heterocyclic group;
  • n is an integer from 0 to 4; for a non-limiting example, m is selected from 0, 1, 2, 3, and 4;
  • n is from 1 to 10, n is a decimal or integer;
  • Pc is an anti-TROP-2 antibody or an antigen-binding fragment thereof.
  • the variable region includes LCDR1, LCDR2, and LCDR3 with the same sequence as the light chain variable region shown in SEQ ID NO: 4.
  • the binding fragment includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes the HCDR1, HCDR2, and HCDR2 shown in SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7, respectively.
  • the light chain variable region includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively.
  • the binding fragment comprises a heavy chain variable region and a light chain variable region, wherein: the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 3 or has at least 90%-100% identity with it, including but not Limited to at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identity and the light chain variable region
  • the amino acid sequence of is shown in SEQ ID NO: 4 or has at least 90%-100% identity with it, including but not limited to at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96% , At least 97%, at least 98%, at least 99%, or at least 100% identity.
  • the binding fragment includes the heavy chain variable region shown in SEQ ID NO: 3 and the light chain variable region shown in SEQ ID NO: 4.
  • the binding fragment comprises a heavy chain constant region and a light chain constant region; preferably, the heavy chain constant region is selected from the constant regions of human IgG1, IgG2, IgG3 and IgG4, and the light chain constant region is selected from the human antibody kappa and lambda chains More preferably, the antibody comprises a heavy chain constant region with a sequence as shown in SEQ ID NO: 11 and a light chain constant region with a sequence as shown in SEQ ID NO: 12.
  • the heavy chain and sequence shown in NO: 15 are the light chain shown in SEQ ID NO: 16; or the heavy chain including the sequence shown in SEQ ID NO: 17 and the light chain shown in SEQ ID NO: 18.
  • n 2 to 10, preferably 4 to 8, n is a decimal or integer.
  • n is 0-10, preferably 1-10, more preferably 1-8, or 2-8, or 2-7, or 2-4, or 3-8, or 3-7, or 3. -6, or 4-7, or 4-6, or 4-5; in some embodiments, n is the average of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 value.
  • Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-;
  • R a and R b are identical or different and are each independently selected from hydrogen atoms, deuterium atoms, halogen and alkyl;
  • R 1 is haloalkyl or C 3-6 cycloalkyl
  • R 2 is selected from hydrogen atom, halogenated alkyl group and C 3-6 cycloalkyl group;
  • R 1 and R 2 together with the carbon atom to which they are attached form a C 3-6 cycloalkyl group
  • m 0 or 1.
  • the O end of Y is connected to the joint unit L.
  • L 1 is selected from -(succinimidyl-3-yl-N)-WC(O)-, -CH 2 -C(O)-NR 3 -WC(O)- and -C(O)-WC( O)-, wherein W is selected from C 1-8 alkyl, C 1-8 alkyl-cycloalkyl and linear heteroalkyl of 1 to 8 atoms, and the heteroalkyl contains 1 to 3 selected from N, O and S heteroatoms, wherein the C 1-8 alkyl, cycloalkyl and linear heteroalkyl are each independently optionally further selected from halogen, hydroxy, cyano, amino, alkyl, Substituted by one or more substituents of chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
  • L 2 is selected from -NR 4 (CH 2 CH 2 O)pCH 2 CH 2 C(O)-, -NR 4 (CH 2 CH 2 O)pCH 2 C(O)-, -S(CH 2 )pC( O)-or chemical bond, where p is an integer from 1 to 20;
  • L 3 is a peptide residue composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from the group consisting of phenylalanine, glycine, valine, lysine, citrulline, serine, and glutamic acid
  • amino acid residue formed with an amino acid in aspartic acid, and optionally further selected from halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl Is substituted by one or more substituents in;
  • L 4 is selected from -NR 5 (CR 6 R 7 ) t -, -C(O)NR 5 , -C(O)NR 5 (CH 2 ) t -and chemical bonds, wherein t is an integer from 1 to 6;
  • R 3 , R 4 and R 5 are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a deuterated alkyl group, and a hydroxyalkyl group;
  • R 6 and R 7 are the same or different, and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group, and a hydroxyalkyl group.
  • L 1 is selected from -(succinimidyl-3-yl-N)-WC(O)-, -CH 2 -C(O)-NR 3 -WC(O)- and -C(O)-WC( O)-, wherein W is selected from the group consisting of C 1-8 alkyl, C 1-8 alkyl-cycloalkyl and linear heteroalkyl of 1 to 8 chain atoms, and the heteroalkyl contains 1 to 3 selected Heteroatoms from N, O and S, wherein the C 1-8 alkyl, cycloalkyl and linear heteroalkyl are each independently optionally further selected from halogen, hydroxy, cyano, amino, alkyl , Substituted by one or more substituents of chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
  • L 2 is selected from -NR 4 (CH 2 CH 2 O)pCH 2 CH 2 C(O)-, -NR 4 (CH 2 CH 2 O)pCH 2 C(O)-, -S(CH 2 )pC( O)-or chemical bond, where p is an integer from 1 to 20;
  • L 3 is a peptide residue composed of 2 to 7 amino acid residues, wherein the amino acid residue is selected from phenylalanine (F), glycine (G), valine (V), lysine ( K), citrulline, serine (S), glutamic acid (Q) and aspartic acid (D) formed by amino acid residues, and optionally further selected from halogen, hydroxyl, cyano, amino , Alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl substituted by one or more substituents;
  • the amino acid residue is selected from phenylalanine (F), glycine (G), valine (V), lysine ( K), citrulline, serine (S), glutamic acid (Q) and aspartic acid (D) formed by amino acid residues, and optionally further selected from halogen, hydroxyl, cyano, amino , Alkyl, chloroalkyl, deuterated alkyl, alkoxy
  • L 4 is selected from -NR 5 (CR 6 R 7 ) t -, -C(O)NR 5 , -C(O)NR 5 (CH 2 ) t -and chemical bonds, where t is an integer from 1 to 6, not The limiting examples are 1, 2, 3, 4, 5 and 6;
  • R 3 , R 4 and R 5 are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a deuterated alkyl group, and a hydroxyalkyl group;
  • R 6 and R 7 are the same or different, and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group, and a hydroxyalkyl group.
  • L 1 is s 1 is an integer from 2 to 8, non-limiting examples are 2, 3, 4, 5, 6, 7 and 8;
  • L 2 is a chemical bond
  • L 3 is a tetrapeptide residue; preferably, L 3 is a tetrapeptide residue of GGFG;
  • L 4 is -NR 5 (CR 6 R 7 )t-, R 5 , R 6 or R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group, and t is 1 or 2;
  • the L 1 terminal is connected to Pc, and the L 4 terminal is connected to Y.
  • the ligand-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any one of the preceding items has the general formula (Pc-L a -YD )
  • W, L 2 , L 3 , R 5 , R 6 , and R 7 are as defined in the aforementioned joint unit -L-;
  • Pc, n, R 1 , R 2 , and m are as defined in the general formula (Pc-LYD).
  • the ligand-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any one of the preceding items has the general formula (Pc-L b -YD )
  • s 1 is an integer from 2 to 8;
  • Pc, R 1 , R 2 , R 5 , R 6 , R 7 , m, and n are as defined in the general formula (Pc-L a -YD).
  • Pc and n are as defined in the general formula (Pc-L-Y-D).
  • n is 4 to 8, n is a decimal or integer
  • Pc is an anti-TROP-2 antibody, which includes a heavy chain as shown in SEQ ID NO: 13 and a light chain as shown in SEQ ID NO: 14.
  • the ligand-drug conjugate represented by the aforementioned general formula (Pc-L-Y-D) or a pharmaceutically acceptable salt thereof, the ligand-drug conjugate is:
  • n is 1 to 8, n is a decimal or an integer, preferably an integer or decimal of 2-4 or 4-8, more preferably an integer or decimal of 4-6;
  • Pc is an anti-TROP-2 antibody, which includes a heavy chain as shown in SEQ ID NO: 13 and a light chain as shown in SEQ ID NO: 14;
  • the ligand-drug conjugate represented by the aforementioned general formula (Pc-L-Y-D) or a pharmaceutically acceptable salt thereof, the ligand-drug conjugate is selected from:
  • n is a decimal or integer from 1 to 8, preferably an integer or decimal of 2-4 or 4-8, more preferably an integer or decimal of 4-6;
  • PD3 is an anti-TROP-2 antibody, which includes a heavy chain as shown in SEQ ID NO: 13 and a light chain as shown in SEQ ID NO: 14;
  • hRS7 is an anti-TROP-2 antibody, or contains a heavy chain as shown in SEQ ID NO: 15 and a light chain as shown in SEQ ID NO: 16;
  • TINA is an anti-TROP-2 antibody, or it contains a heavy chain as shown in SEQ ID NO: 17 and a light chain as shown in SEQ ID NO: 18.
  • the present disclosure also provides an anti-TROP-2 antibody or an antigen-binding fragment thereof, which comprises an antibody heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a sequence such as SEQ ID NO: 3
  • the heavy chain variable region has the same sequence of HCDR1, HCDR2, and HCDR3, and the light chain variable region includes LCDR1, LCDR2, and LCDR3 with the same sequence as the light chain variable region shown in SEQ ID NO: 4.
  • the anti-TROP-2 antibody or antigen-binding fragment thereof as described above comprises a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: HCDR1, HCDR2, and HCDR3, the light chain variable region includes SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10 shows LCDR1, LCDR2 and LCDR3.
  • the anti-TROP-2 antibody or antigen-binding fragment thereof according to any one of the preceding items, wherein the anti-TROP-2 antibody is a murine antibody, a chimeric antibody, a humanized antibody or a human antibody.
  • the anti-TROP-2 antibody or antigen-binding fragment thereof according to any one of the preceding items, which comprises a heavy chain variable region and a light chain variable region, wherein: the amino acid sequence of the heavy chain variable region As shown in SEQ ID NO: 3 or have at least 90%-100% identity with it, including but not limited to at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identity, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 4 or has at least 90%-100% identity with it, including but It is not limited to at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identity.
  • the anti-TROP-2 antibody or antigen-binding fragment thereof comprises an antibody heavy chain constant region and a light chain constant region; preferably Preferably, the heavy chain constant region is selected from human IgG1, IgG2, IgG3 and IgG4 constant regions and conventional variants thereof, and the light chain constant region is selected from human antibody ⁇ and ⁇ chain constant regions and conventional variants thereof; More preferably, the antibody comprises a heavy chain constant region as shown in SEQ ID NO: 11 and a light chain constant region as shown in SEQ ID NO: 12.
  • the anti-TROP-2 antibody or antigen-binding fragment thereof according to any one of the preceding items, wherein the anti-TROP-2 antibody comprises a heavy chain as shown in SEQ ID NO: 13 and a heavy chain as shown in SEQ ID NO: 14 shown in the light chain.
  • the present disclosure provides a nucleic acid molecule that encodes the anti-TROP-2 antibody as described above. In another aspect, the present disclosure provides a nucleic acid molecule that encodes the aforementioned anti-TROP-2 antibody or antigen-binding fragment thereof.
  • the present disclosure provides a host cell comprising the nucleic acid molecule as described above.
  • the present disclosure further provides a method for preparing a ligand-drug conjugate represented by the general formula (Pc-L a -YD) or a pharmaceutically acceptable salt thereof, which comprises the following steps:
  • Pc is an anti-TROP-2 antibody or an antigen-binding fragment thereof
  • n, m, W, L 2 , L 3 , R 1 , R 2 , R 5 , R 6 and R 7 are as defined in the aforementioned general formula (Pc-L a -YD).
  • the present disclosure further provides a method for preparing a ligand-drug conjugate represented by the general formula (Pc-L'-D), which includes the following steps:
  • Pc is the aforementioned anti-TROP-2 antibody or antigen-binding fragment thereof
  • n is as defined in the general formula (Pc-L-Y-D).
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising the ligand-drug conjugate according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the anti-TROP according to any one of the preceding items -2 antibodies or antigen-binding fragments thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.
  • the unit dose of the pharmaceutical composition contains 0.1-3000 mg or 1-1000 mg of the aforementioned anti-TROP-2 antibody or the aforementioned antibody-drug conjugate.
  • the present disclosure provides a ligand-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of the preceding items, or an anti-TROP-2 antibody or an antigen-binding fragment thereof as described in any one of the preceding items, or Its pharmaceutical composition is used as medicine.
  • the present disclosure provides a ligand-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of the preceding items, or an anti-TROP-2 antibody or an antigen-binding fragment thereof as described in any one of the preceding items, or The use of the pharmaceutical composition thereof in the preparation of a medicament for the treatment of a disease or disorder or tumor mediated by TROP-2, wherein the disease or disorder mediated by TROP-2 is a TROP-2 high-expressing cancer, medium-expressing cancer or Low expression cancer.
  • the present disclosure provides a ligand-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of the preceding items, or an anti-TROP-2 antibody or an antigen-binding fragment thereof as described in any one of the preceding items, or comprising it
  • the tumors and cancers are preferably head and neck squamous cell carcinoma, head and neck cancer, brain cancer, glioma, and pleomorphic adult Glioblastoma, neuroblastoma, central nervous system cancer, neuroendocrine tumors, throat cancer, pharyngeal squamous cell carcinoma, oral squamous cell carcinoma, nasopharyngeal carcinoma, esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer , Liver cancer, hepatobiliary cancer, pancreatic cancer, stomach cancer, gastrointestinal cancer,
  • the present disclosure further relates to a method for treating and/or preventing tumors, the method comprising administering to a subject in need thereof a therapeutically effective dose of the ligand-drug conjugate as described in any one of the preceding items Or a pharmaceutically acceptable salt thereof, or the anti-TROP-2 antibody or antigen-binding fragment thereof as described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same; preferably, the tumor is in combination with TROP-2 high expression, medium or low expression related cancers.
  • the present disclosure further relates to a method for treating or preventing tumors or cancers, the method comprising administering to a subject in need thereof a therapeutically effective dose of the ligand-drug conjugate according to any one of the preceding items or A pharmaceutically acceptable salt thereof or the anti-TROP-2 antibody or antigen-binding fragment thereof as described in any one of the preceding items or a pharmaceutical composition comprising the same; wherein the tumor and cancer are preferably head and neck squamous cell carcinoma, head and neck squamous cell carcinoma Neck cancer, brain cancer, glioma, glioblastoma multiforme, neuroblastoma, central nervous system cancer, neuroendocrine tumor, throat cancer, pharyngeal squamous cell carcinoma, oral squamous cell carcinoma, nasopharyngeal carcinoma, esophagus Cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, liver cancer, liver and gallbladder cancer,
  • the present disclosure further provides the aforementioned anti-TROP-2 antibody or its antibody-drug conjugate as a medicine, preferably as a medicine for treating cancer or tumor, and more preferably as a medicine for treating TROP-2 mediated cancer.
  • the active compound for example, the ligand-drug conjugate according to the present disclosure, or a pharmaceutically acceptable salt thereof
  • the unit dose of the active compound or composition described in the present disclosure can be tablet, capsule, cachet, bottled syrup, powder, granule, lozenge, suppository, rejuvenated powder or liquid preparation.
  • the dosage of the active compound or composition used in the treatment methods of the present disclosure will generally vary with the severity of the disease, the weight of the subject and the efficacy of the active compound.
  • a suitable unit dose can be 0.1 mg to 1000 mg.
  • the pharmaceutical composition of the present disclosure may contain one or more excipients selected from the following ingredients: fillers, diluents, binders, wetting agents, disintegrants or excipients, etc. .
  • the composition may contain 0.1 to 99% by weight of the active compound.
  • TROP-2 antibody and antibody-drug conjugate provided in the present disclosure have good affinity with cell surface antigens, good endocytosis efficiency and strong tumor suppression efficiency, and have a wider window of drug application, which is suitable for clinical use Drug application.
  • Figure 1 The results of the binding test of anti-TROP-2 antibody to TROP-2 expressing cells.
  • Figure 2 The bystander killing activity results of ADC on BxPC3 cells and MiaPaCa2 mixed cells.
  • Figure 3 The inhibitory activity of different ADCs on FaDu xenografts in mice.
  • Figure 4 The inhibitory activity of different doses of ADC on SKOV3 transplanted tumors in mice.
  • Figure 5 The inhibitory activity of different doses of ADC on Colo205 xenograft tumors in mice.
  • a trade name When a trade name is used in this disclosure, it is intended to include the formulation of the trade name product, the drug and the active drug portion of the trade name product.
  • cytotoxic drugs refers to cytotoxic drugs, chemical molecules that can strongly disrupt the normal growth of tumor cells.
  • cytotoxic drugs can kill cells at sufficiently high concentrations, but due to lack of specificity, while killing tumor cells, they can also cause normal cell apoptosis, leading to serious side effects.
  • the term includes toxins, such as bacterial, fungal, plant or animal origin, small molecule toxins or enzymatically active toxins, radioactive isotopes (e.g. At 211, I 131, I 125 , Y 90, Re 186, Re 188, Sm 153, Bi 212 , P 32 and Lu radioisotopes), chemotherapeutics, antibiotics and nucleolytic enzymes.
  • linker unit refers to a chemical structure fragment or bond that is connected to a ligand at one end and a drug at the other end. It can also be connected to other linkers before being connected to the ligand or Drugs are connected.
  • the joint may include one or more joint members.
  • exemplary linker building blocks include 6-maleimidohexanoyl ("MC"), maleimidopropionyl ("MP”), valine-citrulline (“val-cit” or “vc "), alanine-phenylalanine (“ala-phe”), p-aminobenzyloxycarbonyl (“PAB”), N-succinimidyl 4-(2-pyridylthio)pentanoate ( “SPP”), N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate (“SMCC”, also referred to herein as "MCC”), and N- Succinimidyl (4-iodo-acetyl) aminobenzoate (“SIAB”).
  • MC 6-maleimidohexanoyl
  • MP maleimidopropionyl
  • val-cit valine-citrulline
  • the linker may be selected from the following elements or combinations thereof: extensions, spacers and amino acid units.
  • the linker can be synthesized by methods known in the art, such as those described in US2005-0238649A1.
  • the linker may be a "cleavable linker" that facilitates the release of the drug in the cell.
  • acid-labile linkers such as hydrazone
  • protease-sensitive such as peptidase-sensitive
  • linkers light-labile linkers, dimethyl linkers, or disulfide-containing linkers
  • U.S. Patent No. 5,208,020 can be used.
  • Joint components include but are not limited to:
  • MC 6-maleimidohexanoyl
  • Val-Cit or "vc” valine-citrulline (an exemplary dipeptide in a protease cleavable linker),
  • Citrulline 2-amino-5-ureidovaleric acid
  • PAB p-aminobenzyloxycarbonyl (example of "self-sacrificing” linker element)
  • Me-Val-Cit N-methyl-valine-citrulline (wherein the linker peptide bond has been modified to prevent it from being cleaved by cathepsin B),
  • MC(PEG)6-OH maleimidohexanoyl-polyethylene glycol (can be attached to antibody cysteine),
  • SPDP N-succinimidyl 3-(2-pyridyldithio)propionate
  • SMCC Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
  • ligand-drug conjugate refers to that the ligand is connected to a drug with biological activity through a linking unit, preferably an "antibody-drug conjugate".
  • ADC antibody-drug conjugate
  • ADC refers to connecting a monoclonal antibody or antibody fragment to a toxic drug with biological activity through a connecting unit.
  • the antibody can be coupled to the drug directly or via a linker.
  • n is the average number of drug modules per antibody, which can be an integer or a decimal, and its range can be: for example, about 0 to about 20 drug modules per antibody, and in some embodiments, 1 to about 10 drug modules per antibody Each drug module, in some embodiments, is 1 to about 8 drug modules per antibody, such as 2, 3, 4, 5, 6, 7, or 8 drug modules.
  • the composition of the antibody-drug conjugate mixture of the present disclosure, wherein the average drug load of each antibody is about 1 to about 10, including but not limited to about 3 to about 7, and about 3 to about 6 One, about 3 to about 5, about 1 to about 9, about 7 or about 4.
  • antibody refers to an immunoglobulin, which is a tetrapeptide chain structure composed of two heavy chains and two light chains connected by interchain disulfide bonds.
  • immunoglobulins can be divided into five categories, or isotypes of immunoglobulins, namely IgM, IgD, IgG, IgA and IgE, and their corresponding The heavy chains are ⁇ chain, ⁇ chain, ⁇ chain, ⁇ chain, and ⁇ chain.
  • the same type of Ig can be divided into different subclasses according to the amino acid composition of the hinge region and the number and position of heavy chain disulfide bonds.
  • IgG can be divided into IgG1, IgG2, IgG3, and IgG4.
  • the light chain is divided into a kappa chain or a lambda chain by the difference of the constant region.
  • Each of the five types of Ig can have a kappa chain or a lambda chain.
  • the sequence of about 110 amino acids near the N-terminus of the full-length antibody heavy and light chains varies greatly and is a variable region (Fv region); the remaining amino acid sequences near the C-terminus are relatively stable and are a constant region.
  • the variable region includes 3 hypervariable regions (HVR) and 4 relatively conserved framework regions (FR). Three hypervariable regions determine the specificity of the antibody, also known as complementarity determining regions (CDR).
  • Each light chain variable region (LCVR) and heavy chain variable region (HCVR) is composed of 3 CDR regions and 4 FR regions.
  • the sequence from the amino terminus to the carboxy terminus is: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the 3 CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the 3 CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.
  • fully human antibody means “fully human antibody”, “fully human antibody”, “human antibody” or “fully human antibody”, also known as “fully human monoclonal antibody”, the variable region and constant region of the antibody are all of human origin , Remove immunogenicity and toxic side effects.
  • the related technologies of fully human antibody preparation mainly include: human hybridoma technology, EBV transformed B lymphocyte technology, phage display technology (phage display), transgenic mouse antibody preparation technology (transgenic mouse) and single B cell antibody preparation technology.
  • antigen-binding fragment refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Fragments of the full-length antibody can be used to perform the antigen-binding function of the antibody.
  • the binding fragment contained in the "antigen-binding fragment” is selected from Fab, Fab', F(ab')2, single-chain antibody (scFv), dimerized V region (diabody), disulfide bond stabilized V region (dsFv) and antigen-binding fragments of peptides containing CDRs, examples include (i) Fab fragments, monovalent fragments composed of VL, VH, CL and CH1 domains; (ii) F(ab') 2 fragments, including through hinge A bivalent fragment of two Fab fragments connected by a disulfide bridge in the region; (iii) Fd fragment composed of VH and CH1 domains; (iv) Fv fragment composed of VH and VL domains of one arm of an antibody;
  • the two domains VL and VH of the Fv fragment are encoded by separate genes, recombination methods can be used to connect them through a synthetic linker so that it can be produced as a single protein in which the VL and VH regions are paired to form a monovalent molecule.
  • Chain referred to as single chain Fv (scFv); see, for example, Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883).
  • single chain antibodies are also intended to be included in the term "antigen-binding fragments" of antibodies.
  • the antigen-binding portion can be produced by recombinant DNA technology or by enzymatic or chemical fragmentation of the intact immunoglobulin.
  • the antibodies may be antibodies of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibodies.
  • Fab is an antibody fragment having a molecular weight of about 50,000 and having antigen-binding activity among fragments obtained by treating IgG antibody molecules with the protease papain (for example, cleaving the amino acid residue at position 224 of the H chain), wherein the H chain The part on the N-terminal side and the L chain are joined together by a disulfide bond.
  • protease papain for example, cleaving the amino acid residue at position 224 of the H chain
  • F(ab')2 is obtained by digesting the lower part of the disulfide bond in the hinge region of IgG with the enzyme pepsin, and has a molecular weight of about 100,000. It has antigen binding activity and contains two Fab regions connected at the hinge position. Antibody fragments.
  • Fab' is an antibody fragment having a molecular weight of about 50,000 and having antigen-binding activity obtained by cleaving the disulfide bond of the hinge region of F(ab')2 described above.
  • the Fab' can be produced by inserting the DNA encoding the Fab' fragment into a prokaryotic expression vector or a eukaryotic expression vector and introducing the vector into a prokaryotic organism or eukaryotic organism to express Fab'.
  • single chain antibody means a molecule comprising an antibody heavy chain variable domain (or VH) and an antibody light chain variable domain (or VL) connected by a linker.
  • Such scFv molecules may have the general structure: NH 2 -VL-linker-VH-COOH or NH 2 -VH-linker-VL-COOH.
  • Suitable prior art linkers consist of a repeated GGGGS amino acid sequence or variants thereof, for example using 1-4 repeated variants (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448) .
  • linkers that can be used in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996) , Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.
  • CDR refers to one of the six hypervariable regions in the variable domain of an antibody that mainly contribute to antigen binding.
  • CDR there are three CDRs (HCDR1, HCDR2, HCDR3) in each heavy chain variable region, and three CDRs (LCDR1, LCDR2, LCDR3) in each light chain variable region.
  • Any one of various well-known schemes can be used to determine the amino acid sequence boundaries of CDRs, including the "Kabat” numbering rule (see Kabat et al.
  • the CDR in the variable domain of the heavy chain (VH) The amino acid residue numbers are 31-35 (HCDR1), 50-65 (HCDR2) and 95-102 (HCDR3); the CDR amino acid residue numbers in the light chain variable domain (VL) are 24-34 (LCDR1), 50 -56 (LCDR2) and 89-97 (LCDR3).
  • the CDR amino acids in VH are numbered 26-32 (HCDR1), 52-56 (HCDR2) and 95-102 (HCDR3); and the amino acids in VL
  • the residue numbers are 26-32 (LCDR1), 50-52 (LCDR2) and 91-96 (LCDR3).
  • the CDR is defined by the amino acid residues 26-35 (HCDR1) in human VH. ), 50-65 (HCDR2) and 95-102 (HCDR3) and the amino acid residues 24-34 (LCDR1), 50-56 (LCDR2) and 89-97 (LCDR3) in human VL.
  • HCDR1 amino acid residues 26-35
  • HCDR2 amino acid residues 26-65
  • HCDR3 amino acid residues 24-34
  • LCDR1, 50-56 (LCDR2) and 89-97 (LCDR3) in human VL follow the IMGT rules, VH
  • the CDR amino acid residue numbers in VL are roughly 26-35 (CDR1), 51-57 (CDR2) and 93-102 (CDR3)
  • the CDR amino acid residue numbers in VL are roughly 27-32 (CDR1), 50-52 (CDR2) and 89-97 (CDR3).
  • the CDR region of an antibody can be determined using the program IMGT/DomainGap Align.
  • frame region refers to a part of the variable domain VL or VH, which serves as a scaffold for the antigen binding loop (CDR) of the variable domain. Essentially, it is a variable domain without CDRs.
  • epitope or "antigenic determinant” refers to a site on an antigen that is bound by an immunoglobulin or antibody. Epitopes usually include at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or non-contiguous amino acids in a unique spatial conformation. See, for example, Epitope Mapping Protocols in Methods in Molecular B iology, Volume 66, G.E. Morris, Ed. (1996).
  • the terms “specifically binds”, “selectively binds”, “selectively binds” and “specifically binds” refer to the binding of an antibody or a fragment thereof to an epitope on a predetermined antigen. Generally, the antibody or fragment thereof binds with an affinity (KD) of about less than 10 -7 M, for example, about less than 10 -8 M, 10 -9 M, or 10 -10 M or less.
  • KD affinity
  • KD refers to the dissociation equilibrium constant of the antibody-antigen interaction.
  • the antibody or antigen-binding fragment of the present disclosure binds to TROP-2 or its epitope with a dissociation equilibrium constant (KD) of less than about 10 -7 M, for example, less than about 10 -8 M or 10 -9 M, for example,
  • KD dissociation equilibrium constant
  • the affinity between the antibody and the cell surface antigen is determined by the FACS method to determine the KD value.
  • nucleic acid molecule refers to a DNA molecule or an RNA molecule.
  • the nucleic acid molecule may be single-stranded or double-stranded, but is preferably double-stranded DNA.
  • the nucleic acid is "operably linked.” For example, if a promoter or enhancer affects the transcription of a coding sequence, then the promoter or enhancer is effectively linked to the coding sequence.
  • Amino acid sequence identity refers to the process of aligning amino acid sequences, introducing gaps when necessary to achieve the maximum percentage of sequence identity, and not considering any conservative substitutions as part of sequence identity.
  • the percentage of amino acid residues that have the same amino acid residues in the sequence can be achieved in a variety of ways within the technical scope of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software.
  • BLAST BLAST-2
  • ALIGN ALIGN
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2 ALIGN-2
  • ALIGN-2
  • expression vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • the vector is a "plasmid”, which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated.
  • the vector is a viral vector in which additional DNA segments can be ligated into the viral genome.
  • the vectors disclosed herein can replicate autonomously in the host cell into which they have been introduced (for example, bacterial vectors with a bacterial origin of replication and episomal mammalian vectors) or can be integrated into the genome of the host cell after being introduced into the host cell, so as to follow The host genome replicates together (e.g., a non-episomal mammalian vector).
  • the methods for producing and purifying antibodies and antigen-binding fragments are well known in the prior art, such as Cold Spring Harbor’s Antibody Experiment Technical Guide, Chapters 5-8 and 15.
  • the antibodies or antigen-binding fragments of the invention are genetically engineered to add one or more human FR regions to the non-human CDR regions.
  • the human FR germline sequence can be obtained from the website of ImmunoGeneTics (IMGT) by comparing the IMGT human antibody variable region germline gene database and MOE software, or from the Immunoglobulin Journal, Lefranc, G., The Immunoglobulin FactsBook, Academic Press , Obtained on 2001ISBN012441351.
  • host cell refers to a cell into which an expression vector has been introduced.
  • Host cells may include microorganisms (such as bacteria), plant or animal cells.
  • Bacteria that are easily transformed include members of the enterobacteriaceae, such as Escherichia coli or Salmonella strains; Bacillaceae such as Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae.
  • Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris.
  • Suitable animal host cell lines include CHO (Chinese Hamster Ovary cell line) and NS0 cells.
  • the engineered antibodies or antigen-binding fragments of the present disclosure can be prepared and purified by conventional methods.
  • the cDNA sequences encoding the heavy and light chains can be cloned and recombined into an expression vector.
  • the recombinant immunoglobulin expression vector can be stably transfected into host cells.
  • mammalian expression systems can lead to glycosylation of antibodies, especially at the N-terminal site of the Fc region.
  • Positive clones are expanded in the culture medium of the bioreactor to produce antibodies.
  • the culture medium from which the antibody is secreted can be purified by conventional techniques. For example, use A or G Sepharose FF column for purification. Wash away non-specifically bound components.
  • the bound antibody was eluted by the pH gradient method, and the antibody fragment was detected by SDS-PAGE and collected.
  • the antibody can be filtered and concentrated by conventional methods. Soluble mixtures and polymers can also be removed by conventional methods, such as molecular sieves and ion exchange. The resulting product needs to be frozen immediately, such as -70°C, or lyophilized.
  • peptide refers to a molecule composed of two or more amino acid molecules connected to each other through peptide bonds, and is a structural and functional fragment of a protein.
  • alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably containing 1 to 12 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atom alkyl group, more preferably an alkyl group containing 1 to 10 carbon atoms, most preferably containing 1 to 6 carbon atoms (including 1, 2, 3 1, 4, 5, or 6 carbon atoms).
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-Dimethylpropyl, 2,2-Dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -Methylhexyl, 3-methylhexyl, 4-methylhe
  • lower alkyl groups containing 1 to 6 carbon atoms More preferred are lower alkyl groups containing 1 to 6 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and sec-butyl.
  • Alkyl groups may be substituted or unsubstituted.
  • substituents When substituted, substituents may be substituted at any available attachment point.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkanes Group, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane Oxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo.
  • heteroalkyl refers to an alkyl group containing one or more heteroatoms selected from N, O or S, wherein the alkyl group is as defined above.
  • alkylene refers to a saturated linear or branched aliphatic hydrocarbon group, which has a residue derived from the removal of two hydrogen atoms from the same carbon atom or two different carbon atoms of the parent alkane, which contains 1 A straight or branched chain group of to 20 carbon atoms, preferably containing 1 to 12 (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms, More preferably, an alkylene group containing 1 to 6 carbon atoms (including 1, 2, 3, 4, 5, or 6 carbon atoms).
  • Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH 2 -), 1,1-ethylene (-CH(CH 3 )-), 1,2-ethylene (-CH 2 -) CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene (-CH 2 CH 2 CH 2 -), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2 -) and 1,5-butylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -) Wait.
  • the alkylene group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment.
  • the substituent is preferably independently optionally selected from alkyl, alkenyl, alkynyl , Alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy , Cycloalkylthio, heterocycloalkylthio and oxo groups are substituted by one or more substituents.
  • alkoxy refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where the definition of alkyl or cycloalkyl is as described above.
  • alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy.
  • the alkoxy group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio.
  • haloalkyl refers to the replacement of hydrogen on an alkyl group with one or more halogens, where the alkyl group is as defined above.
  • deuterated alkyl refers to the replacement of hydrogen on an alkyl group with one or more deuterium atoms, where the alkyl group is as defined above.
  • hydroxyalkyl means that the hydrogen on an alkyl group is replaced by one or more hydroxy groups, where the alkyl group is as defined above.
  • hydroxy refers to the -OH group.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • amino refers to -NH 2 .
  • nitro refers to -NO 2 .
  • cyano refers to -CN.
  • the present disclosure also includes compounds of formula (Pc-L-Y-D) in various deuterated forms.
  • Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom.
  • Those skilled in the art can synthesize the compound of formula (Pc-L-Y-D) in the deuterated form with reference to relevant literature.
  • Commercially available deuterated starting materials can be used when preparing the deuterated form of the compound of formula (Pc-LYD), or they can be synthesized using conventional techniques using deuterated reagents.
  • Deuterated reagents include, but are not limited to, deuterated borane, three Deuterated borane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.
  • heterocyclic group optionally substituted by an alkyl group means that an alkyl group may but does not have to be present, and the description includes the case where the heterocyclic group is substituted by an alkyl group and the case where the heterocyclic group is not substituted by an alkyl group.
  • Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, and more preferably 1, 2, or 3 hydrogen atoms are independently substituted with substituents. Substituents are only in their possible chemical positions, and those skilled in the art can determine (through experiment or theory) possible or impossible substitutions without too much effort. For example, an amino group or a hydroxyl group having free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., ethylenic) bond.
  • pharmaceutical composition means a mixture containing one or more of the compounds described herein or their physiologically/pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically/pharmaceutically acceptable Carriers and excipients.
  • the purpose of the pharmaceutical composition is to promote the administration to the organism, which is beneficial to the absorption of the active ingredient and thus the biological activity.
  • pharmaceutically acceptable salt refers to the salt of the antibody-drug conjugate of the present disclosure. Such salt is safe and effective when used in a subject, and has due Biologically active, the ligand-drug conjugate of the present disclosure contains at least one amino group, so it can form a salt with an acid.
  • Non-limiting examples of pharmaceutically acceptable salts include: hydrochloride, hydrobromide, hydroiodide, and sulfate , Bisulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, pearate, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, Tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate.
  • drug loading refers to the average amount of cytotoxic drug loaded on each ligand in the ligand-drug conjugate, and can also be expressed as the ratio of drug amount to antibody amount, drug loading
  • the range can be 0-12 per ligand (Pc), preferably 1-10 cytotoxic drugs.
  • the drug loading is expressed as n, which can also be referred to as the DAR (Drug-antibody Ratio) value, and exemplary are 1, 2, 3, 4, 5, 6, 7, 8, 9, Average of 10.
  • Conventional methods such as UV/visible light spectroscopy, mass spectrometry, ELISA test and HPLC characteristics can be used to identify the average number of drug products per ADC molecule after the coupling reaction.
  • the cytotoxic drug is coupled to the sulfhydryl group of the antibody through a linking unit.
  • the following non-limiting methods can be used to control the loading of the ligand-drug conjugate, including:
  • carrier used for the drugs of the present disclosure refers to a system that can change the way the drug enters the human body and its distribution in the body, control the release rate of the drug, and deliver the drug to the targeted organ.
  • the drug carrier release and targeting system can reduce drug degradation and loss, reduce side effects, and improve bioavailability.
  • polymer surfactants that can be used as carriers can self-assemble to form various forms of aggregates due to their unique amphiphilic structure.
  • Preferred examples are micelles, microemulsions, gels, liquid crystals, vesicles, etc. . These aggregates have the ability to contain drug molecules and at the same time have good permeability to the membrane, and can be used as excellent drug carriers.
  • excipient is an add-on other than the main drug in a pharmaceutical preparation, and can also be referred to as an adjuvant.
  • adjuvant such as binders, fillers, disintegrants, lubricants in tablets; base parts in semi-solid preparations ointments and creams; preservatives, antioxidants, correctives, fragrances, etc. in liquid preparations
  • Cosolvents, emulsifiers, solubilizers, osmotic pressure regulators, colorants, etc. can all be called excipients.
  • diluent is also called a filler, and its main purpose is to increase the weight and volume of the tablet.
  • the addition of diluent not only guarantees a certain volume, but also reduces the deviation of the dosage of the main components, and improves the compression molding of the drug.
  • an absorbent should be added to absorb the oily substance to keep it in a "dry” state to facilitate the manufacture of tablets.
  • the pharmaceutical composition may be in the form of a sterile injectable aqueous solution.
  • a sterile injectable aqueous solution Among the acceptable solvents and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution.
  • the sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase.
  • the active ingredient is dissolved in a mixture of soybean oil and lecithin.
  • the oil solution is added to a mixture of water and glycerin to form a microemulsion.
  • the injection or microemulsion can be injected into the bloodstream of the subject by local large-volume injection.
  • a continuous intravenous delivery device can be used.
  • An example of such a device is the Deltec CADD-PLUS.TM. 5400 intravenous pump.
  • the pharmaceutical composition may be in the form of a sterile injection water or oil suspension for intramuscular and subcutaneous administration.
  • the suspension can be formulated according to known techniques using those suitable dispersing or wetting agents and suspending agents mentioned above.
  • the sterile injection preparation may also be a sterile injection solution or suspension prepared in a non-toxic parenterally acceptable diluent or solvent, for example, a solution prepared in 1,3-butanediol.
  • sterile fixed oil can be conveniently used as a solvent or suspending medium. For this purpose, any blended fixed oil including synthetic mono- or diglycerides can be used.
  • fatty acids such as oleic acid can also be used to prepare injections.
  • the preparation method of the compound represented by the general formula (Pc-L a -YD) includes the following steps:
  • the reducing agent is preferably TCEP, in particular, the disulfide bond on the antibody is preferably reduced;
  • Pc, W, L 2 , L 3 , R 1 , R 2 , R 5 , R 6 , R 7 , m, and n are as defined in the aforementioned general formula (Pc-L a -YD).
  • TROP-2 on the surface of CHO-K1 cells infected with lentivirus was detected by FACS, and the CHO-K1/hTROP-2 monoclonal cell line with high TROP-2 expression was selected.
  • TROP-2 (Genbank: NP_002344.2) is as follows:
  • the anti-human TROP-2 monoclonal antibody in this application is prepared according to the method disclosed in the WO03074566 patent, using the hRS7 antibody variable region gene as a template and using computer software to design point mutations for CDR. It is inserted into the protein expression vector Phr-IgG (with signal peptide and constant region gene (CH1-Fc/CL) fragment) by molecular cloning, and expressed in HEK293 and Expi-CHO-S cells. Purify the antibody according to the conventional method. CHO-K1 cells overexpressing huTROP-2 protein and huTROP-2 protein (His27-Thr274 accession number #NP_002344.2) were used for activity verification, and antibodies with better target binding activity were selected.
  • the PD3 variable region sequence is as follows :
  • the underlined part is the CDR region determined according to the Kabat numbering rules.
  • the heavy chain constant region of the antibody can be selected from the constant regions of human IgG1, IgG2, IgG4 and variants thereof, and the light chain constant region can be selected from the light chain constant regions of human kappa, lambda chains or their variants.
  • the antibody heavy chain constant region is selected from the human IgG1 sequence shown in SEQ ID NO: 11, and the light chain constant region is selected from the human kappa chain constant region shown in SEQ ID NO: 12.
  • the heavy chain constant region of human IgG1 is the heavy chain constant region of human IgG1
  • the above-mentioned light chain/heavy chain constant region is combined with the variable region of the above-mentioned PD3 antibody to form a complete antibody, and the light chain/heavy chain sequence is as follows:
  • control molecule hRS7 used in the present disclosure was constructed with reference to patent WO03074566, and the TINA antibody was constructed with reference to patent WO2015098099A1.
  • sequences are as follows:
  • the experimental methods without specific conditions in the embodiments of the present disclosure usually follow the conventional conditions or the conditions suggested by the raw material or commodity manufacturers.
  • the reagents without specific sources are the conventional reagents purchased on the market.
  • the structure of the compound is determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR is measured with Bruker AVANCE-400 nuclear magnetic instrument, the solvent is deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD), and the internal standard is tetramethyl sulfoxide (DMSO-d6) Based on silane (TMS), the chemical shift is given in units of 10 -6 (ppm).
  • NMR nuclear magnetic resonance
  • MS mass spectrometry
  • HPLC determination uses Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18 150 ⁇ 4.6mm chromatographic column) and Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150 ⁇ 4.6mm chromatographic column).
  • the UV-HPLC measurement uses a Thermonanodrop2000 ultraviolet spectrophotometer.
  • the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the size of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm to 0.2mm, and the size of the thin layer chromatography separation and purification product is 0.4mm. To 0.5mm silica gel plate.
  • the known starting materials of the present disclosure can be synthesized by or according to methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Companies such as Darui Chemicals.
  • the reactions are all carried out under an argon atmosphere or a nitrogen atmosphere.
  • the argon atmosphere or nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon with a volume of about 1L.
  • the hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon with a volume of about 1L.
  • the pressure hydrogenation reaction uses Parr 3916EKX hydrogenator and Qinglan QL-500 hydrogen generator or HC2-SS hydrogenator.
  • the hydrogenation reaction is usually evacuated and filled with hydrogen, and the operation is repeated 3 times.
  • the microwave reaction uses the CEM Discover-S 908860 microwave reactor.
  • the solution in the reaction refers to an aqueous solution.
  • reaction temperature is room temperature.
  • Room temperature is the most suitable reaction temperature, and the temperature range is 20°C to 30°C.
  • the preparation of the PBS buffer with pH 6.5 in the examples: take KH 2 PO 4 8.5g, K 2 HPO 4 .3H 2 O 8.56g, NaCl 5.85g, and EDTA 1.5g in a bottle, dilute the volume to 2L, and ultrasonic Dissolve all of it, shake well and get it.
  • the eluent system of column chromatography and the developing solvent system of thin layer chromatography used to purify compounds include: A: dichloromethane and isopropanol system, B: dichloromethane and methanol system, C: petroleum ether and In the ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine and acidic or alkaline reagents can also be added for adjustment.
  • Q-TOF LC/MS uses Agilent 6530 accurate mass quadrupole-time-of-flight mass spectrometer and Agilent 1290-Infinity ultra-high performance liquid chromatograph (Agilent Poroshell 300SB-C8 5 ⁇ m, 2.1 ⁇ 75mm column).
  • the reaction solution was concentrated under reduced pressure, and the obtained crude compound 2 was purified by high performance liquid chromatography (separation conditions: chromatographic column: XBridge Prep C18 OBD 5um 19*250mm; mobile phase: A-water (10mmol NH 4 OAc), B- Acetonitrile, gradient elution, flow rate: 18 mL/min), collect the corresponding components, and concentrate under reduced pressure to obtain the title product (2-A: 1.5 mg, 2-B: 1.5 mg).
  • reaction was quenched by adding 5 mL of water to the reaction solution, the reaction solution was extracted with ethyl acetate (10 mL ⁇ 3), the organic phases were combined, washed with saturated sodium chloride solution (5 mL ⁇ 2), and the organic phase was dried with anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with the developing solvent system B to obtain the title product 4 (2.5 mg, yield: 80.9%).
  • the benzyl 1-hydroxycyclopropane-1-carboxylate 8a (104mg, 0.54mmol; prepared by the method disclosed in the patent application "US2005/20645”) and 2-((((9H-fluoren-9-yl) Methoxy) carbonyl) amino) acetamido) methyl acetate 8b (100 mg, 0.27 mmol; prepared by the method disclosed in the patent application "CN105829346A”) was added to the reaction flask, 5 mL of tetrahydrofuran was added, argon replaced three times, ice The temperature of the water bath was cooled to 0-5°C, potassium tert-butoxide (61mg, 0.54mmol) was added, the ice bath was removed, and the temperature was raised to room temperature and stirred for 10 minutes.
  • reaction solution was purified by high performance liquid chromatography (separation conditions: column: XBridge Prep C18 OBD 5um 19*250mm; mobile phase: A-water (10mmol NH 4 OAc): B-acetonitrile, gradient elution, flow rate: 18mL/ min), collect the corresponding components, and concentrate under reduced pressure to obtain the title product 8 (2mg, yield: 39.0%).
  • the obtained residue was dissolved in 4 mL of dioxane, 2 mL of water was added, sodium bicarbonate (49.2 mg, 0.586 mmol) and 9-fluorenylmethyl chloroformate (126 mg, 0.49 mmol) were added, and the mixture was stirred at room temperature for 2 hours. 20 mL of water was added, extracted with ethyl acetate (10 mL ⁇ 3), the organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography with the developing solvent system C to obtain the title product 9b (48 mg, yield: 19%).
  • Dissolve 9d (19 mg, 22.6 ⁇ mol) in 2 mL of dichloromethane, add 1 mL of diethylamine, and stir at room temperature for 2 hours.
  • the reaction solution was concentrated under reduced pressure, 1 mL of toluene was added and concentrated under reduced pressure, repeated twice.
  • the solid residue was concentrated under reduced pressure and pulled dry by an oil pump to obtain the crude title product 9e (17 mg), which was directly used in the next reaction without purification.
  • reaction solution was purified by high performance liquid chromatography (separation conditions: column: XBridge Prep C18 OBD 5um 19*250mm; mobile phase: A-water (10mmol NH 4 OAc): B-acetonitrile, gradient elution, flow rate: 18mL/ min), the corresponding components were collected and concentrated under reduced pressure to obtain the title product (9-A: 2.4 mg, 9-B: 1.7 mg).
  • UV-Vis calculated average: n 3.77.
  • UV-Vis calculated average value: n 6.59.
  • UV-Vis calculated average value: n 4.14.
  • UV-Vis calculated average: n 3.99.
  • Embodiment 3-5 ADC-5
  • UV-Vis calculated average value: n 3.88.
  • Dissolve compound SN38 (synthesized according to Example 1 on page 59 of patent CN105407891A, 2.1mg, 1419 nmol) in 50 ⁇ L DMSO, add it to the above reaction solution, place it in a water bath shaker, shake the reaction at 25°C for 3 hours, stop reaction.
  • the reaction solution was desalted and purified with a Sephadex G25 gel column (elution phase: 0.05M PBS buffer aqueous solution with pH 6.5) to obtain an exemplary title product ADC-6 represented by the formula hRS7-SN38 in PBS buffer solution (1.03 mg /mL, 11.5mL), stored at 4°C.
  • UV-Vis calculated average value: n 3.72.
  • UV-Vis calculated average: n 3.93.
  • UV-Vis calculated average: n 3.99.
  • ADC is a kind of antibody cross-linked drug.
  • the mechanism of its treatment of diseases is to rely on the targeting of antibodies to transport toxin molecules into cells, thereby killing the cells.
  • the load of the drug plays a decisive role in the efficacy of the drug.
  • the UV method was used to determine the drug load of the ADC stock solution.
  • Ultraviolet spectrophotometry using instrument: Thermonanodrop2000 ultraviolet spectrophotometer
  • the principle is that the total absorbance of ADC stock at a certain wavelength is equal to the absorbance of cytotoxic drugs and monoclonal antibodies at this wavelength.
  • a 280nm ⁇ mab-280 bC mab + ⁇ Drug-280 bC Drug
  • ⁇ Drug-280 The average molar extinction coefficient of the drug at 280nm is 5100;
  • ⁇ mab-280 The average molar extinction coefficient of single antigen solution at 280nm is 214600;
  • C mab concentration of single antigen solution
  • the optical path length is 1 cm.
  • a 370nm ⁇ mab-370 bC mab + ⁇ Drug-370 bC Drug
  • ⁇ Drug-370 The average molar extinction coefficient of the drug at 370nm is 19000;
  • ⁇ mab-370 The extinction coefficient of single antigen solution at 370nm is 0;
  • C mab concentration of single antigen solution
  • the optical path length is 1 cm.
  • the drug loading can be calculated.
  • Drug load C Drug /C mab .
  • SDS-Mw Analysis Kit produced by Beckman, item number 390953.
  • the kit contains SDS-MW gel separation buffer, SDS-MW sample buffer, acid cleaning solution (0.1mol/L hydrochloric acid solution), and alkaline cleaning solution ( 0.1mol sodium hydroxide solution), internal standard substance (10kDa).
  • the SDS kit produced by Beijing Bosiya Institute of Biochemical Technology, article number BSYK018, can also be used.
  • the kit contains CE-SDS gel buffer and CE-SDS sample buffer.
  • Alkylation solution (0.25mo iodoacetamide solution): Weigh about 0.046g iodoacetamide, add 1mL ultrapure water to dissolve and mix, and store at 2-8°C in the dark for 7 days.
  • Capillary electrophoresis instrument SCIEX company PA800plus.
  • Capillary Uncoated fused silica capillary (inner diameter 50 ⁇ m), cut to a total length of 30.2cm, and the effective separation length of the high-resolution method is 20cm.
  • test substance Dilute the test substance to 1 mg/mL with SDS sample buffer. Take 95 ⁇ L of the test solution (1mg/mL), add 5 ⁇ L of 0.8mol/L iodoacetamide aqueous solution, and vortex to mix. Take 95 ⁇ L of the blank control, add 5 ⁇ L of 0.8mol/L iodoacetamide aqueous solution, vortex to mix, and respectively take out 75 ⁇ L from the sample tube to the sample bottle for analysis immediately.
  • SDS gel separation buffer is flushed under 50 psi pressure for 15 minutes. It should be done before each run.
  • Sample injection 10kV reverse polarity electric injection, reducing sample injection for 20 seconds.
  • Capillary temperature 18 to 25°C.
  • the data is analyzed with Beckman software, and the calibration peak areas of the heavy chain, non-glycosylated heavy chain, and light chain account for all the calibration peaks. Area calculation.
  • DAR [4*heavy chain (H) peak area+2*semi-antibody (HL) peak area+4*double chain (HH) peak area+2*heavy heavy light chain (HHL) peak area]/[heavy Chain (H) peak area / 2 + semi-antibody (HL) peak area / 2 + double chain (HH) peak area + heavy and light chain (HHL) peak area + total antibody peak area], and finally calculate the weighted average of the ADC value.
  • Test Example 1 Antibody protein level binding experiment
  • the hTROP-2 protein was diluted to 1 ⁇ g/mL with pH 7.4 PBS (Yuan Pei Biological, B320) buffer, and added to a 96-well microtiter plate at a volume of 100 ⁇ L/well, and incubated overnight at 4°C. After the liquid was discarded, 300 ⁇ L of 5% skimmed milk (BD, 232100) diluted with PBS was added to each well for blocking, and incubated at 37°C for 2 hours.
  • pH 7.4 PBS pH 7.4 PBS
  • BD, 232100 5% skimmed milk
  • PBST buffer pH7.4PBS containing 0.1% tween-20
  • 100 ⁇ L of gradiently diluted antibody solution was added to each well and incubated at 37°C for 1 hour.
  • the plate was washed 3 times with PBST, 100 ⁇ L mouse anti-human IgG (H+L) (Jackson ImmunoResearch, 209-035-088, 1:8000 dilution) was added to each well, and incubated at 37°C for 1 hour.
  • TMB chromogenic substrate KPL, 5120-00757
  • 50 ⁇ L 1M H 2 SO 4 50 ⁇ L 1M H 2 SO 4
  • the absorbance value at 450nm is fitted to the binding curve of the antibody and the antigen with software, and the EC 50 value is calculated.
  • the binding activity of antibody and protein is shown in Table 2.
  • Antibody PD3 hRS7 TINA Emax (OD value) 1.40 1.37 1.39 EC50(nM) 13.6 18.29 16.14
  • Test Example 2 Antibody cell-level binding experiment
  • FACS buffer 2% fetal bovine serum (Gibco, 10099141) pH 7.4 PBS (Sigma, P4417-100TAB)
  • FACS buffer 2% fetal bovine serum (Gibco, 10099141) pH 7.4 PBS (Sigma, P4417-100TAB)
  • the holes are added to the 96-well round bottom plate. After removing the supernatant by centrifugation, add 50 ⁇ L/well of the antibody to be tested in different concentrations diluted with FACS buffer, and incubate for 1 hour in a refrigerator at 4°C in the dark.
  • the purpose of this experiment is to kill the cells based on the activated DT after the DT3C protein enters the cells, which indirectly reflects the endocytosis of anti-TROP-2 antibodies.
  • the endocytic activity of the antibody in vitro was evaluated based on EC 50 and Emax.
  • DT3C is a recombinantly expressed fusion protein, which is formed by fusion of fragment A (toxin part only) of diphtheria toxin and 3C fragment (IgG binding part) of group G streptococci. This protein can have a high affinity with the IgG part of the antibody.
  • endocytosis occurs, it enters the cell together and releases toxic DT under the action of intracellular furin.
  • DT can inhibit the activity of EF2-ADP ribosylation, block the protein translation process, and ultimately lead to cell death.
  • the DT3C that has not entered the cell has no cell-killing activity.
  • the endocytosis activity of the antibody is evaluated according to the cell killing situation.
  • the cell suspension was prepared with fresh cell culture medium containing 20% low IgG FBS at a cell density of 2 ⁇ 10 4 cells/mL, 50 ⁇ L/well was added to the cell culture plate, and 5% carbon dioxide was incubated at 37° C. for 16 hours.
  • the endocytosis activity of the antibody is shown in Table 4.
  • the detection of antibody affinity to TROP-2 is in the form of capture antibody.
  • a Protein A (Cat.#29127556,GE) biosensing chip coupled with an anti-human IgG antibody (Cat.#BR-1008-39, Lot.#10260416, GE) was used to affinity capture the antibody, and then on the chip surface Flow through the antigen hTROP-2, and use the Biacore T200 instrument to detect the reaction signal in real time to obtain the binding and dissociation curves. After the dissociation of each experimental cycle is completed, the chip is washed and regenerated with regeneration buffer Glycine1.5 (Cat#BR100354, GE) or 3M MgCl 2 (from Human antibody capture kit, Cat.#BR100839, GE). After the experiment, GE Biacore T200Evaluation version 3.0 software was used to fit the data with a (1:1) Langmuir model to obtain the affinity value. The affinities of antibodies and proteins are shown in Table 5.
  • the cells used in this experiment are as follows: FaDu(++++) purchased from ATCC, item number HTB-43 TM ; HCC827(+++), purchased from ATCC, item number CRL-2868; Colo205(++), purchased from Chinese Academy of Sciences Cell bank, item number: TCHu102; DMS53(++), purchased from ATCC, item number: CRL-2062 TM ; SK-OV-3(+), purchased from ATCC, item number: HTB-77; CHO-K1(-), Purchased from ATCC, article number: CCL-61 TM .
  • “+” means the expression level of TROP-2 in the cells, the more "+”, the higher the expression level of TROP-2, and the "-" means that TROP-2 is not expressed.
  • the cell suspension was prepared with fresh cell culture medium containing 10% FBS at a density of 3703 cells/mL, and 135 ⁇ L per well was added to a 96-well cell culture plate, and incubated with 5% carbon dioxide at 37°C for 16 hours.
  • ADC samples were prepared with PBS to 5 ⁇ M. With this as the first concentration, it was diluted five-fold with PBS for a total of 8 concentrations. Add 15 ⁇ L of the above ADC solution to each well. Incubate at 37°C for 6 days with 5% carbon dioxide. Add 70 ⁇ L CTG to each well, incubate for 10 minutes in the dark at room temperature, read chemiluminescence on Victor3 and use GraphPad Prism software for data analysis.
  • ADC-1 has a strong cell killing effect, and the killing effect is positively correlated with the expression level of TROP-2 on the surface of tumor cells.
  • BxPC3 human pancreatic cancer cells, ATCC, CRL-1687
  • MiaPaCa2 cells human pancreatic cancer cells, biocytogen, B-HCL-014
  • RPMI1640 + 10% FBS and DMEM/high glucose + 10% FBS respectively. Trypsin digestion, neutralization with fresh medium, centrifugation at 1000 rpm for 3 minutes, discarding the supernatant, and resuspending the cells with RPMI1640+10% FBS. After the cell count, the density of BxPC3 cells was adjusted to 6 ⁇ 10 4 cells/mL, and the density of MiaPaCa2-luc cells was adjusted to 1.5 ⁇ 10 4 cells/mL.
  • ADC samples were prepared into a 40 ⁇ concentration intermediate solution (0.2 ⁇ M). Take 25 ⁇ L of the above samples and add them to the corresponding wells of the 12-well plate. Set up a solvent control group. Incubate at 37°C for 6 days with 5% carbon dioxide. The cells in the 12-well plate were digested with trypsin, neutralized with fresh medium, centrifuged at 1000 rpm for 3 minutes, the supernatant was discarded, and resuspended in 1 mL of FACS buffer (PBS+2.5% FBS), and 20 ⁇ L of cells were added to the 20 ⁇ L platform. Panlan, count.
  • FACS buffer PBS+2.5% FBS
  • the cells in plate 1 were centrifuged at 1000 rpm for 3 minutes, the supernatant was discarded, and the supernatant was resuspended in 100 ⁇ L of FACS Buffer, and 2 ⁇ L of TROP-2 (EGP-1) monoclonal antibody (MR54) was added, and incubated on ice for 30 minutes. Centrifuge at 2000 rpm for 1 minute at 4°C, discard the supernatant, and add 150 ⁇ L FACS buffer to resuspend the cells. Use BD FACSVerse to detect. Use Flowjo 7.6 to analyze the data. The results of the bystander killing activity experiment are shown in Figure 2.
  • ADC-1 in the present disclosure has a clear bystander killing effect.
  • ADC does not kill TROP-2 negative MiaPaCa2 cells, but after mixing BxPC3 cells expressing TROP-2 with negative cells MiaPaCa2, ADC-1 TROP-2 negative cells also have a killing effect.
  • Test Example 7 In vivo drug efficacy evaluation of Fadu cell CDX mouse model
  • Fadu cells (3 ⁇ 10 6 cells) were inoculated subcutaneously into the right ribs of Balb/c nude mice. After 10 days of inoculation, when the tumor volume was ⁇ 245 mm 3 , the body weight, the tumor was too large and too small, were removed, and the mice were divided according to the tumor volume. They were randomly divided into 5 groups, each with 8 animals.
  • ADC intraperitoneal injection was administered twice on day 0 and day 8. Each animal was injected with 10g/0.1mL according to body weight, and the dose was 1mg/kg. The tumor volume and body weight were measured twice a week, and the data was recorded for a total of 21 days.
  • V tumor volume
  • T/C(%) (TT 0 )/(CC 0 ) ⁇ 100, where T and C are the tumor volumes of the treatment group and the control group at the end of the experiment; T 0 , C 0 are the tumor volumes at the beginning of the experiment Tumor volume.
  • TGI (%) 1-T/C (%).
  • Test Example 8 In vivo drug efficacy evaluation of SKOV3 cell CDX mouse model
  • SKOV3 cells (5 ⁇ 10 6 cells) were inoculated subcutaneously into the right ribs of Balb/c nude mice. 23 days after the inoculation, after the tumor volume was about 180 mm 3 , the body weight, the tumor was too large and too small, were removed, and the mice were divided according to the tumor volume. They were randomly divided into 5 groups, each with 8 animals.
  • ADC intraperitoneal injection a total of 2 administrations, each injection of 10g/0.1mL according to body weight, the dosage is shown in the table below.
  • the tumor volume and body weight were measured twice a week, and the data was recorded.
  • V tumor volume
  • T/C(%) (TT 0 )/(CC 0 ) ⁇ 100, where T and C are the tumor volumes of the treatment group and the control group at the end of the experiment; T 0 , C 0 are the tumor volumes at the beginning of the experiment Tumor volume.
  • TGI (%) 1-T/C (%).
  • ADC-1 has a strong anti-tumor effect on SKOV3 transplanted tumors, and the anti-tumor effect has a dose-dependent effect.
  • the effect has a dose-dependent effect.
  • Test Example 9 In vivo drug efficacy evaluation of Colo205 cell CDX mouse model
  • Colo205 cells (5 ⁇ 10 6 cells) were inoculated subcutaneously into the right ribs of Balb/c nude mice. After 10 days of inoculation, after the tumor volume was ⁇ 245mm 3 , the body weight, the tumor was too large and too small, were removed, and the mice were divided according to the tumor volume. They were randomly divided into 6 groups with 8 animals in each group.
  • ADC intraperitoneal injection was administered twice on day 0 (D0) and day 10, and each animal was injected with 10g/0.1mL according to body weight, and the dose was 10mg/kg.
  • the tumor volume and body weight were measured twice a week, and the data were recorded for 28 days (D28).
  • V tumor volume
  • T/C(%) (TT 0 )/(CC 0 ) ⁇ 100, where T and C are the tumor volumes of the treatment group and the control group at the end of the experiment; T 0 , C 0 are the tumor volumes at the beginning of the experiment Tumor volume.
  • TGI (%) 1-T/C (%).

Abstract

本发明提供了抗TROP-2抗体-依喜替康类似物偶联物及其医药用途。具体而言，本发明提供了如通式(Pc-L-Y-D)所示的抗TROP-2抗体-依喜替康类似物偶联物，其中Pc为抗TROP-2抗体或其抗原结合片段。

Description

抗TROP-2抗体-依喜替康类似物偶联物及其医药用途
本申请要求2020年1月22日提交的中国专利申请(申请号CN 202010073438.8)的优先权。
技术领域
本公开涉及抗TROP-2抗体、抗TROP-2抗体-依喜替康类似物偶联物，其制备方法，包含其的药物组合物，以及其用于制备治疗TROP-2介导的疾病或病症的药物中的用途；尤其在用于制备抗癌药物中的用途。
背景技术
这里的陈述仅提供与本公开有关的背景信息，而不必然地构成现有技术。
TROP-2是人滋养层细胞表面糖蛋白抗原2，又名肿瘤相关钙离子信号转导子2(TACSTD2)、表皮糖蛋白1(EGP-1)、胃肠肿瘤相关抗原(GA733-1)、表面标志物1(M1S1)，是由染色体1p32区域的Tacstd2基因编码表达的细胞表面糖蛋白。TROP-2属GA733蛋白家族，与上皮细胞黏附分子(EpCAM，又称Trop1、TACSTD1)有较高结构序列相似性，同源性达49％。
TROP-2蛋白初级结构是由约323个氨基酸组成的约36kD的多肽，初级结构经N-端糖基化翻译后修饰，形成不同于EpCAM的I型细胞膜糖蛋白，即TROP-2蛋白。TROP-2蛋白横跨细胞膜，N-端为胞外域(Trop2EC)，该胞外域通过一个单向跨膜螺旋(TM)与由26个氨基酸残基构成的疏水性多肽的胞内短尾(Trop2IC)连接，从而固定于胞膜。
目前发现TROP-2在胚胎发育和肿瘤细胞增殖转移的过程中具有重要意义。TROP-2最初发现于滋养层细胞，并作为其表面标志物，滋养细胞源于胚胎外滋养层，TROP-2有助于胚胎着床及胎盘组织形成，并且在胚胎干细胞增殖特性维持以及器官形成发展过程中发挥重要作用。除此之外，TROP-2还是重要的肿瘤发展相关因子，其高表达于多种肿瘤，如胰腺癌、乳腺癌、结肠癌、胃癌、口腔鳞癌、卵巢癌等，可促进肿瘤细胞增殖、侵袭、转移扩散等过程，其高表达与肿瘤受试者生存期缩短及不良预后密切相关，因此以TROP-2为靶点的抗肿瘤药物研究具有重要意义。
抗体-药物偶联物(antibody drug conjugate，ADC)将单克隆抗体或者抗体片段通过接头化合物与具有生物活性的细胞毒素相连，充分利用了抗体对正常细胞和肿瘤细胞表面抗原结合的特异性和细胞毒性物质的高效性，同时又避免了抗体的疗效偏低和毒性物质的毒副作用过大等缺陷。这也就意味着，与以往传统的化疗药物相比，抗体-药物偶联物能更精准地杀伤肿瘤细胞并降低将对正常细胞的影响。
发明内容
本公开涉及抗TROP-2抗体，其ADC以及其用途，提供与抗TROP-2抗体或抗原结合片段与细胞毒性物质依喜替康类似物偶联的ADC药物。
本公开提供了一种通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐：
Figure PCTCN2021073279-appb-000001
其中：
Y选自-O-(CR aR b) m-CR 1R 2-C(O)-、-O-CR 1R 2-(CR aR b) m-、-O-CR 1R 2-、-NH-(CR aR b) m-CR 1R 2-C(O)-和-S-(CR aR b) m-CR 1R 2-C(O)-；
R a和R b相同或不同，且各自独立地选自氢原子、氘原子、卤素、烷基、卤代烷基、氘代烷基、烷氧基、羟基、氨基、氰基、硝基、羟烷基、环烷基和杂环基；或者，R a和R b与其相连接的碳原子一起形成环烷基或杂环基；
R 1选自卤素、卤代烷基、氘代烷基、环烷基、环烷基烷基、烷氧基烷基、杂环基、芳基和杂芳基；R 2选自氢原子、卤素、卤代烷基、氘代烷基、环烷基、环烷基烷基、烷氧基烷基、杂环基、芳基和杂芳基；或者，R 1和R 2与其相连接的碳原子一起形成环烷基或杂环基；
或者，R a和R 2与其相连的碳原子一起形成环烷基或杂环基；
m为0至4的整数；非限制性实施例如m选自0、1、2、3和4；
n为1至10，n是小数或整数；
L为接头单元；
Pc为抗TROP-2抗体或其抗原结合片段。
在一些实施方案中，如前所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含重链可变区和轻链可变区，其中所述重链可变区包含与如SEQ ID NO：3所示的重链可变区相同序列的HCDR1、HCDR2和HCDR3，所述轻链可变区包含与如SEQ ID NO：4所示的轻链可变区相同序列的LCDR1、LCDR2和LCDR3。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含重链可变区和轻链可变区，其中所述重链可变区包含分别如SEQ ID NO：5、SEQ  ID NO：6和SEQ ID NO：7所示的HCDR1、HCDR2和HCDR3，所述轻链可变区包含分别如SEQ ID NO：8、SEQ ID NO：9和SEQ ID NO：10所示的LCDR1、LCDR2和LCDR3。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体是鼠源抗体、嵌合抗体、人源化抗体或人抗体。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含重链可变区和轻链可变区，其中：所述重链可变区的氨基酸序列如SEQ ID NO:3所示或与其有至少90％-100％同一性，包括但不限于至少91％、至少92％、至少93％、至少94％，至少95％、至少96％、至少97％、至少98％、至少99％或至少100％同一性和所述轻链可变区的氨基酸序列如SEQ ID NO:4所示或与其有至少90％-100％同一性，包括但不限于至少91％、至少92％、至少93％、至少94％，至少95％、至少96％、至少97％、至少98％、至少99％或至少100％同一性。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含序列如SEQ ID NO:3所示的重链可变区和序列如SEQ ID NO：4所示的轻链可变区。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含重链恒定区和轻链恒定区；优选地，所述重链恒定区选自人IgG1、IgG2、IgG3和IgG4的恒定区，所述轻链恒定区选自人抗体κ和λ链的恒定区；更优选地，所述抗体包含序列如SEQ ID NO:11所示的重链恒定区和序列如SEQ ID NO:12所示的轻链恒定区。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体包含如SEQ ID NO：13所示的重链和如SEQ ID NO：14所示的轻链。
在一些实施方案中，如前所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体包含序列如SEQ ID NO:15所示的重链和序列如SEQ ID NO：16所示的轻链；或者包含序列如SEQ ID NO:17所示的重链和序列如SEQ ID NO：18所示的轻链。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中n为2至10，优选为4至8，n是小数或整数。在一些实施方案中，n为0-10，优选1-10，更优选1-8，或2-8，或2-7，或2-4，或3-8，或3-7，或3-6，或4-7，或4-6，或4-5的平均值；在一些实施方案中，n为1，2，3，4，5，6，7，8，9，10的平均值。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，
其中：
Y为-O-(CR aR b) m-CR 1R 2-C(O)-；
R a和R b相同或不同，且各自独立地选自氢原子、氘原子、卤素和烷基；
R 1为卤代烷基或C 3-6环烷基；
R 2选自氢原子、卤代烷基和C 3-6环烷基；
或者，R 1和R 2与其相连接的碳原子一起形成C 3-6环烷基；
m为0或1。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中Y选自：
Figure PCTCN2021073279-appb-000002
其中Y的O端与接头单元L相连。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中接头单元-L-为-L 1-L 2-L 3-L 4-，
L 1选自-(琥珀酰亚胺-3-基-N)-W-C(O)-、-CH 2-C(O)-NR 3-W-C(O)-和-C(O)-W-C(O)-，其中W选自C 1-8烷基、C 1-8烷基-环烷基和1至8个原子的直链杂烷基，所述杂烷基包含1至3个选自N、O和S的杂原子，其中所述的C 1-8烷基、环烷基和直链杂烷基各自独立地任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基的一个或多个取代基所取代；
L 2选自-NR 4(CH 2CH 2O)pCH 2CH 2C(O)-、-NR 4(CH 2CH 2O)pCH 2C(O)-、-S(CH 2)pC(O)-或化学键，其中p为1至20的整数；
L 3为由2至7个氨基酸残基构成的肽残基，其中所述的氨基酸残基选自苯丙氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、谷氨酸和天冬氨酸中的氨基酸形成的氨基酸残基，并任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基中的一个或多个取代基所取代；
L 4选自-NR 5(CR 6R 7) t-、-C(O)NR 5、-C(O)NR 5(CH 2) t-和化学键，其中t为1至6的整数；
R 3、R 4和R 5相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、氘代烷基和羟烷基；
R 6和R 7相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氘 代烷基和羟烷基。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中接头单元-L-为-L 1-L 2-L 3-L 4-，
L 1选自-(琥珀酰亚胺-3-基-N)-W-C(O)-、-CH 2-C(O)-NR 3-W-C(O)-和-C(O)-W-C(O)-，其中W选自C 1-8烷基、C 1-8烷基-环烷基和1至8个链原子的直链杂烷基，所述杂烷基包含1至3个选自N、O和S的杂原子，其中所述的C 1-8烷基、环烷基和直链杂烷基各自独立地任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基的一个或多个取代基所取代；
L 2选自-NR 4(CH 2CH 2O)pCH 2CH 2C(O)-、-NR 4(CH 2CH 2O)pCH 2C(O)-、-S(CH 2)pC(O)-或化学键，其中p为1至20的整数；
L 3为由2至7个氨基酸残基构成的肽残基，其中所述的氨基酸残基选自苯丙氨酸(F)、甘氨酸(G)、缬氨酸(V)、赖氨酸(K)、瓜氨酸、丝氨酸(S)、谷氨酸(Q)和天冬氨酸(D)中的氨基酸形成的氨基酸残基，并任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基中的一个或多个取代基所取代；
L 4选自-NR 5(CR 6R 7) t-、-C(O)NR 5、-C(O)NR 5(CH 2) t-和化学键，其中t为1至6的整数，非限制性实施例为1，2，3，4，5和6；
R 3、R 4和R 5相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、氘代烷基和羟烷基；
R 6和R 7相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氘代烷基和羟烷基。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中接头单元-L-为-L 1-L 2-L 3-L 4-，
L 1为
Figure PCTCN2021073279-appb-000003
s 1为2至8的整数，非限制性实施例为2，3，4，5，6，7和8；
L 2为化学键；
L 3为四肽残基；优选地，L 3为GGFG的四肽残基；
L 4为-NR 5(CR 6R 7)t-，R 5、R 6或R 7相同或不同，且各自独立地为氢原子或烷基，t为1或2；
其中所述的L 1端与Pc相连，L 4端与Y相连。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中-L-为：
Figure PCTCN2021073279-appb-000004
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中-L-Y-任选自：
Figure PCTCN2021073279-appb-000005
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其为通式(Pc-L a-Y-D)所示的配体-药物偶联物或其药学上可接受的盐：
Figure PCTCN2021073279-appb-000006
其中：
W、L 2、L 3、R 5、R 6、R 7如前所述接头单元-L-中所定义；
Pc、n、R 1、R 2、m如通式(Pc-L-Y-D)中所定义。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其为通式(Pc-L b-Y-D)所示的配体-药物偶联物或其药学上可接受的盐：
Figure PCTCN2021073279-appb-000007
其中：
s 1为2至8的整数；
Pc、R 1、R 2、R 5、R 6、R 7、m和n如通式(Pc-L a-Y-D)中所定义。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，所述配体-药物偶联物选自：
Figure PCTCN2021073279-appb-000008
其中Pc和n如通式(Pc-L-Y-D)中所定义。
在一些实施方案中，如前任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，所述配体-药物偶联物选自：
Figure PCTCN2021073279-appb-000009
其中：
n为4至8，n是小数或整数；
Pc为抗TROP-2抗体，其包含如SEQ ID NO:13所示的重链和如SEQ ID NO：14所示的轻链。
在一些实施方案中，如前所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，所述配体-药物偶联物是：
Figure PCTCN2021073279-appb-000010
其中：
n为1至8，n是小数或整数，优选2-4或者4-8的整数或小数，更优选4-6的整数或小数；
Pc为抗TROP-2抗体，其包含如SEQ ID NO:13所示的重链和如SEQ ID NO：14所示的轻链；
或者包含如SEQ ID NO:15所示的重链和如SEQ ID NO：16所示的轻链；
或者包含如SEQ ID NO:17所示的重链和如SEQ ID NO：18所示的轻链。
在一些实施方案中，如前所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，所述配体-药物偶联物选自：
Figure PCTCN2021073279-appb-000011
其中：
n为1至8的小数或整数，优选2-4或者4-8的整数或小数，更优选4-6的整数或小数；
PD3为抗TROP-2抗体，其包含如SEQ ID NO:13所示的重链和如SEQ ID NO：14所示的轻链；
hRS7为抗TROP-2抗体，或者包含如SEQ ID NO:15所示的重链和如SEQ ID NO：16所示的轻链；
TINA为抗TROP-2抗体，或者包含如SEQ ID NO:17所示的重链和如SEQ ID NO：18所示的轻链。
本公开还提供了一种抗TROP-2抗体或其抗原结合片段，其包含抗体重链可变区和轻链可变区，其中所述重链可变区包含与如SEQ ID NO：3序列的重链可变区相同序列的HCDR1、HCDR2和HCDR3，所述轻链可变区包含与如SEQ ID NO：4所示的轻链可变区相同序列的LCDR1、LCDR2和LCDR3。
在一些实施方案中，如前所述的抗TROP-2抗体或其抗原结合片段，其包含重链可变区和轻链可变区，其中：所述重链可变区包含分别如SEQ ID NO：5、SEQ ID NO：6和SEQ ID NO：7所示的HCDR1、HCDR2和HCDR3，所述轻链可变区包含分别如SEQ ID NO：8、SEQ ID NO：9和SEQ ID NO：10所示的 LCDR1、LCDR2和LCDR3。
在一些实施方案中，如前任一项所述的抗TROP-2抗体或其抗原结合片段，其中所述抗TROP-2抗体是鼠源抗体、嵌合抗体、人源化抗体或人抗体。
在一些实施方案中，如前任一项所述的抗TROP-2抗体或其抗原结合片段，其包含重链可变区和轻链可变区，其中：所述重链可变区的氨基酸序列如SEQ ID NO:3所示或与其有至少90％-100％的同一性，包括但不限于至少91％、至少92％、至少93％、至少94％，至少95％、至少96％、至少97％、至少98％、至少99％或至少100％同一性，和所述轻链可变区的氨基酸序列如SEQ ID NO:4所示或与其有至少90％-100％同一性，包括但不限于至少91％、至少92％、至少93％、至少94％，至少95％、至少96％、至少97％、至少98％、至少99％或至少100％同一性。
在一些实施方案中，如前任一项所述的抗TROP-2抗体或其抗原结合片段，其中所述抗TROP-2抗体或其抗原结合片段包含抗体重链恒定区和轻链恒定区；优选地，所述重链恒定区选自人IgG1、IgG2、IgG3和IgG4的恒定区及其常规变体，所述轻链恒定区选自人抗体κ和λ的链恒定区及其常规变体；更优选地，所述抗体包含如SEQ ID NO:11所示的重链恒定区和如SEQ ID NO:12所示的轻链恒定区。
在一些实施方案中，如前任一项所述的抗TROP-2抗体或其抗原结合片段，其中所述抗TROP-2抗体包含如SEQ ID NO:13所示的重链和如SEQ ID NO：14所示的轻链。
另一方面，本公开提供了一种核酸分子，其编码如前所述的抗TROP-2抗体。另一方面，本公开提供了一种核酸分子，其编码如前所述的抗TROP-2抗体或其抗原结合片段。
另一方面，本公开提供了一种宿主细胞，其包含如前所述的核酸分子。
本公开进一步提供一种制备如通式(Pc-L a-Y-D)所示的配体-药物偶联物或其药学上可接受的盐的方法，其包括以下步骤：
Figure PCTCN2021073279-appb-000012
Pc还原后，与通式(L a-Y-D)所示的化合物进行偶联反应，得到通式(Pc-L a-Y-D)所示的化合物；
其中：
Pc为抗TROP-2抗体或其抗原结合片段；
n、m、W、L 2、L 3、R 1、R 2、R 5、R 6和R 7如前述通式(Pc-L a-Y-D)中所定义。
本公开进一步提供一种制备如通式(Pc-L’-D)所示的配体药物偶联物的方法，其包括以下步骤：
Figure PCTCN2021073279-appb-000013
Pc还原后，与式(L’-D)所示的化合物进行偶联反应，得到通式(Pc-L’-D)所示的化合物；其中：
Pc为如前所述的抗TROP-2抗体或其抗原结合片段；
n如通式(Pc-L-Y-D)中所定义。
另一方面，本公开提供了一种药物组合物，其包含根据如前任一项所述的配体-药物偶联物或其药学上可接受的盐，或如前任一项所述的抗TROP-2抗体或其抗原结合片段，以及一种或多种药学上可接受的赋形剂、稀释剂或载体。在一些实施方案中，所述单位剂量的药物组合物中含有0.1-3000mg或1-1000mg如前所述的抗TROP-2抗体或如前所述的抗体-药物偶联物。
另一方面，本公开提供了如前任一项所述的配体-药物偶联物或其药学上可接受的盐或如前任一项所述的抗TROP-2抗体或其抗原结合片段或包含其的药物组合物作为药物的用途。
另一方面，本公开提供了如前任一项所述的配体-药物偶联物或其药学上可接受的盐或如前任一项所述的抗TROP-2抗体或其抗原结合片段或包含其的药物组合物在制备用于治疗TROP-2介导的疾病或病症或肿瘤的药物中的用途其中所述TROP-2介导的疾病或病症为TROP-2高表达癌症，中表达癌症或低表达癌症。
另一方面，本公开提供如前任一项所述的配体-药物偶联物或其药学上可接受的盐或如前任一项所述的抗TROP-2抗体或其抗原结合片段或包含其的药物组合物在制备用于治疗或预防肿瘤的药物中的用途，其中所述肿瘤和癌症优选头和颈鳞状细胞癌、头和颈癌、脑癌、神经胶质瘤、多形性成胶质细胞瘤、神经母细胞瘤、中枢神经系统癌、神经内分泌肿瘤、咽喉癌、咽鳞癌、口腔鳞癌、鼻咽癌、食管癌、甲状腺癌、恶性胸膜间皮瘤、肺癌、乳腺癌、肝癌、肝胆癌、胰腺癌、胃癌、胃肠道癌、肠癌、结肠癌、结肠直肠癌、肾癌、透明细胞肾细胞癌、卵巢 癌、子宫内膜癌、子宫颈癌、膀胱癌、前列腺癌、睾丸癌、皮肤癌、黑色素瘤、白血病、淋巴瘤、骨癌、软骨肉瘤、骨髓瘤、多发性骨髓瘤、骨髓异常增生综合征、库肯勃氏瘤、骨髓增生性肿瘤、鳞状细胞癌、尤因氏肉瘤、尿路上皮癌和梅克尔细胞癌；更优选的，所述淋巴瘤选自：何杰金淋巴瘤、非何杰金淋巴瘤、弥漫性大B-细胞淋巴瘤、滤泡性淋巴瘤、原发性纵隔大B-细胞淋巴瘤、套细胞淋巴瘤、小淋巴细胞性淋巴瘤、富含T-细胞/组织细胞的大B-细胞淋巴瘤和淋巴浆细胞性淋巴瘤，所述肺癌选自：非小细胞肺癌和小细胞肺癌，所述白血病选自：慢性髓细胞样白血病、急性髓细胞样白血病、淋巴细胞白血病、成淋巴细胞性白血病、急性成淋巴细胞性白血病、慢性淋巴细胞性白血病和髓样细胞白血病。
另一方面，本公开进一步涉及一种用于治疗和/或预防肿瘤的方法，该方法包括向需要其的受试者施用治疗有效剂量的如前任一项所述的配体-药物偶联物或其药学上可接受的盐或如前任一项所述的抗TROP-2抗体或其抗原结合片段或其药学上可接受的盐或包含其的药物组合物；优选其中所述的肿瘤为与TROP-2高表达，中表达或低表达相关的癌症。
另一方面，本公开进一步涉及一种用于治疗或预防肿瘤或癌症的方法，该方法包括向需要其的受试者施用治疗有效剂量的如前任一项所述的配体药物偶联物或其药学上可接受的盐或如前任一项所述的抗TROP-2抗体或其抗原结合片段或包含其的药物组合物；其中所述肿瘤和癌症优选头和颈鳞状细胞癌、头和颈癌、脑癌、神经胶质瘤、多形性成胶质细胞瘤、神经母细胞瘤、中枢神经系统癌、神经内分泌肿瘤、咽喉癌、咽鳞癌、口腔鳞癌、鼻咽癌、食管癌、甲状腺癌、恶性胸膜间皮瘤、肺癌、乳腺癌、肝癌、肝胆癌、胰腺癌、胃癌、胃肠道癌、肠癌、结肠癌、结肠直肠癌、肾癌、透明细胞肾细胞癌、卵巢癌、子宫内膜癌、子宫颈癌、膀胱癌、前列腺癌、睾丸癌、皮肤癌、黑色素瘤、白血病、淋巴瘤、骨癌、软骨肉瘤、骨髓瘤、多发性骨髓瘤、骨髓异常增生综合征、库肯勃氏瘤、骨髓增生性肿瘤、鳞状细胞癌、尤因氏肉瘤、尿路上皮癌和梅克尔细胞癌；更优选的，所述淋巴瘤选自：何杰金淋巴瘤、非何杰金淋巴瘤、弥漫性大B-细胞淋巴瘤、滤泡性淋巴瘤、原发性纵隔大B-细胞淋巴瘤、套细胞淋巴瘤、小淋巴细胞性淋巴瘤、富含T-细胞/组织细胞的大B-细胞淋巴瘤和淋巴浆细胞性淋巴瘤，所述肺癌选自：非小细胞肺癌和小细胞肺癌，所述白血病选自：慢性髓细胞样白血病、急性髓细胞样白血病、淋巴细胞白血病、成淋巴细胞性白血病、急性成淋巴细胞性白血病、慢性淋巴细胞性白血病和髓样细胞白血病。
另一方面，本公开进一步提供前述的抗TROP-2抗体或其抗体-药物偶联物作为药物，优选作为治疗癌症或肿瘤的药物，更优选作为治疗TROP-2介导的癌症的药物。
可将活性化合物(例如根据本公开所述的配体-药物偶联物、或其药学上可接受的盐)制成适合于通过任何适当途径给药的形式，活性化合物优选是以单位剂 量的方式，或者是以受试者能够以单位剂量进行自我给药的方式。本公开所述的活性化合物或组合物的单位剂量的方式可以是片剂、胶囊、扁囊剂、瓶装药水、药粉、颗粒剂、锭剂、栓剂、再生药粉或液体制剂。
本公开治疗方法中所用活性化合物或组合物的施用剂量通常将随疾病的严重性、受试者的体重和活性化合物的功效而改变。作为一般性指导，合适的单位剂量可以是0.1mg至1000mg。
本公开的药物组合物除活性化合物外，可含有一种或多种辅料，所述辅料选自以下成分：填充剂、稀释剂、粘合剂、润湿剂、崩解剂或赋形剂等。根据给药方法的不同，组合物可含有0.1至99重量％的活性化合物。
本公开提供的TROP-2抗体及抗体-药物偶联物具有与细胞表面抗原良好的亲和力，良好的细胞内吞效率和很强的肿瘤抑制效率，并且具有更宽的药物应用窗口，适于临床的药物应用。
附图说明
图1：抗TROP-2抗体与表达TROP-2的细胞结合实验结果。
图2：ADC对BxPC3细胞和MiaPaCa2混合细胞的旁观杀伤活性结果。
图3：不同ADC对小鼠体内FaDu移植瘤的抑制活性。
图4：不同剂量的ADC对小鼠体内SKOV3移植瘤的抑制活性。
图5：不同剂量的ADC对小鼠体内Colo205移植瘤的抑制活性。
具体实施方式
一.术语
除非另有限定，本文所用的所有技术和科学术语均与本公开所属领域普通技术人员的通常理解一致。虽然也可采用与本文所述相似或等同的任何方法和材料实施或测试本公开，但本文描述了优选的方法和材料。描述和要求保护本公开时，依据以下定义使用下列术语。
当本公开中使用商品名时，旨在包括该商品名产品的制剂、该商品名产品的药物和活性药物部分。
除非有相反陈述，在说明书和权利要求书中使用的术语具有下述含义。
术语“药物”是指细胞毒性药物，能在肿瘤细胞内具有较强破坏其正常生长的化学分子。细胞毒性药物原则上在足够高的浓度下都可以杀死细胞，但是由于缺乏特异性，在杀伤肿瘤细胞的同时，也会导致正常细胞的凋亡，导致严重的副作用。该术语包括毒素，如细菌、真菌、植物或动物来源的小分子毒素或酶活性毒素，放射性同位素(例如At 211、I 131、I 125、Y 90、Re 186、Re 188、Sm 153、Bi 212、P 32和Lu的放射性同位素)，化疗药物，抗生素和核溶酶。
术语“接头单元”、“接头”、“连接单元”或“连接片段”是指一端与配体连 接而另一端与药物相连的化学结构片段或键，也可以连接其他接头后再与配体或药物相连。
接头可以包含一种或多种接头构件。示例性的接头构件包括6-马来酰亚氨基己酰基(“MC”)、马来酰亚氨基丙酰基(“MP”)、缬氨酸-瓜氨酸(“val-cit”或“vc”)、丙氨酸-苯丙氨酸(“ala-phe”)、对氨基苄氧羰基(“PAB”)、N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯(“SPP”)、N-琥珀酰亚氨基4-(N-马来酰亚氨基甲基)环己烷-1羧酸酯(“SMCC”，在本文中也称作“MCC”)和N-琥珀酰亚氨基(4-碘-乙酰基)氨基苯甲酸酯(“SIAB”)。接头可以选自以下的元件或其组合：延伸物、间隔物和氨基酸单元。可以通过本领域已知方法合成接头，诸如US2005-0238649A1中所记载的。接头可以是便于在细胞中释放药物的“可切割接头”。例如，可使用酸不稳定接头(例如腙)、蛋白酶敏感(例如肽酶敏感)接头、光不稳定接头、二甲基接头、或含二硫化物接头(Chari等,Cancer Research 52:127-131(1992)；美国专利No.5,208,020)。
接头元件包括但不限于：
MC＝6-马来酰亚氨基己酰基，结构如下：
Figure PCTCN2021073279-appb-000014
Val-Cit或“vc”＝缬氨酸-瓜氨酸(蛋白酶可切割接头中的示例二肽)，
瓜氨酸＝2-氨基-5-脲基戊酸，
PAB＝对氨基苄氧羰基(“自我牺牲”接头元件的示例)，
Me-Val-Cit＝N-甲基-缬氨酸-瓜氨酸(其中接头肽键已经修饰以防止其受到组织蛋白酶B的切割)，
MC(PEG)6-OH＝马来酰亚氨基己酰基-聚乙二醇(可附着于抗体半胱氨酸)，
SPP＝N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯，
SPDP＝N-琥珀酰亚氨基3-(2-吡啶基二硫代)丙酸酯，
SMCC＝琥珀酰亚氨基-4-(N-马来酰亚氨基甲基)环己烷-1-羧酸酯，
IT＝亚氨基硫烷。
术语“配体-药物偶联物”指配体通过连接单元与具有生物活性的药物相连，优选为“抗体-药物偶联物”。在本公开中“抗体-药物偶联物”(antibody drug conjugate，ADC)，指将单克隆抗体或者抗体片段通过连接单元与具有生物活性的毒性药物相连。抗体可直接地或经接头地偶联至药物。n是每个抗体的平均药物模块数，可以是整数或小数，其范围可以是：例如每个抗体约0到约20个药物模块，在某些实施方案中是每个抗体1个到约10个药物模块，在某些实施方案中是每个抗体1个到约8个药物模块，如2、3、4、5、6、7、8个药物模块。本公开的抗体-药物偶联物的混合物的组合物，其中每个抗体的平均药物载荷是约1个至约10 个，包括但不限于约3个至约7个，约3个至约6个，约3个至约5个，约1个至约9个，约7个或约4个。
本公开所用氨基酸三字母代码和单字母代码如J.biol.chem,243,p3558(1968)中所述。
术语“抗体”指免疫球蛋白，是由两条重链和两条轻链通过链间二硫键连接而成的四肽链结构。根据免疫球蛋白重链恒定区的氨基酸组成和排列顺序不同，可将免疫球蛋白分为五类，或称为免疫球蛋白的同种型，即IgM、IgD、IgG、IgA和IgE，其相应的重链分别为μ链、δ链、γ链、α链、和ε链。同一类Ig根据其铰链区氨基酸组成和重链二硫键的数目和位置的差别，又可分为不同的亚类，如IgG可分为IgG1、IgG2、IgG3、IgG4。轻链通过恒定区的不同分为κ链或λ链。五类Ig中每类Ig都可以有κ链或λ链。
全长抗体重链和轻链靠近N端的约110个氨基酸的序列变化很大，为可变区(Fv区)；靠近C端的其余氨基酸序列相对稳定，为恒定区。可变区包括3个高变区(HVR)和4个序列相对保守的框架区(FR)。3个高变区决定抗体的特异性，又称为互补性决定区(CDR)。每条轻链可变区(LCVR)和重链可变区(HCVR)由3个CDR区4个FR区组成，从氨基端到羧基端依次排列的顺序为：FR1，CDR1，FR2，CDR2，FR3，CDR3，FR4。轻链的3个CDR区指LCDR1、LCDR2、和LCDR3；重链的3个CDR区指HCDR1、HCDR2和HCDR3。
术语“完全人源抗体”、“完全人抗体”、“人抗体”或“全人抗体”，也称“全人源单克隆抗体”，其抗体的可变区和恒定区都是人源的，去除免疫原性和毒副作用。全人源抗体制备的相关技术主要有：人杂交瘤技术、EBV转化B淋巴细胞技术、噬菌体显示技术(phage display)、转基因小鼠抗体制备技术(transgenic mouse)和单个B细胞抗体制备技术等。
术语“抗原结合片段”是指抗体的保持特异性结合抗原的能力的一个或多个片段。可利用全长抗体的片段来进行抗体的抗原结合功能。“抗原结合片段”中包含的结合片段选自Fab、Fab'、F(ab')2、单链抗体(scFv)、二聚化的V区(双抗体)、二硫键稳定化的V区(dsFv)和包含CDR的肽的抗原结合片段，示例包括(i)Fab片段，由VL、VH、CL和CH1结构域组成的单价片段；(ii)F(ab') 2片段，包含通过铰链区上的二硫桥连接的两个Fab片段的二价片段；(iii)由VH和CH1结构域组成的Fd片段；(iv)由抗体的单臂的VH和VL结构域组成的Fv片段；(v)单结构域或dAb片段(Ward等人,(1989)Nature341：544-546)，其由VH结构域组成；和(vi)分离的互补决定区(CDR)或(vii)可任选地通过合成的接头连接的两个或更多个分离的CDR的组合。此外，虽然Fv片段的两个结构域VL和VH由分开的基因编码，但可使用重组方法，通过合成的接头连接它们，从而使得其能够产生为其中VL和VH区配对形成单价分子的单个蛋白质链(称为单链Fv(scFv)；参见，例如，Bird等人(1988)Science242:423-426；和Huston 等人(1988)Proc.Natl.Acad.Sci USA85:5879-5883)。此类单链抗体也意欲包括在术语抗体的“抗原结合片段”中。使用本领域技术人员已知的常规技术获得此类抗体片段，并且以与对于完整抗体的方式相同的方式就功用性筛选片段。可通过重组DNA技术或通过酶促或化学断裂完整免疫球蛋白来产生抗原结合部分。抗体可以是不同同种型的抗体，例如，IgG(例如，IgG1，IgG2，IgG3或IgG4亚型)，IgA1，IgA2，IgD，IgE或IgM抗体。
通常，Fab是通过用蛋白酶木瓜蛋白酶(例如，切割H链的224位的氨基酸残基)处理IgG抗体分子所获得的片段中的具有约50,000的分子量并具有抗原结合活性的抗体片段，其中H链N端侧的部分和L链通过二硫键结合在一起。
通常，F(ab')2是通过用酶胃蛋白酶消化IgG铰链区中二硫键的下方部分而获得的，分子量约为100,000，并具有抗原结合活性并包含在铰链位置相连的两个Fab区的抗体片段。
通常，Fab'是通过切割上述F(ab')2的铰链区的二硫键而获得的分子量为约50,000并具有抗原结合活性的抗体片段。
此外，可以通过将编码Fab'片段的DNA插入到原核生物表达载体或真核生物表达载体中并将载体导入到原核生物或真核生物中以表达Fab'来生产所述Fab'。
术语“单链抗体”、“单链Fv”或“scFv”意指包含通过接头连接的抗体重链可变结构域(或VH)和抗体轻链可变结构域(或VL)的分子。此类scFv分子可具有一般结构：NH 2-VL-接头-VH-COOH或NH 2-VH-接头-VL-COOH。合适的现有技术接头由重复的GGGGS氨基酸序列或其变体组成，例如使用1-4个重复的变体(Holliger等人(1993)，Proc.Natl.Acad.Sci.USA90:6444-6448)。可用于本公开的其他接头由Alfthan等人(1995)，Protein Eng.8:725-731，Choi等人(2001)，Eur.J.Immuno l.31:94-106，Hu等人(1996)，Cancer Res.56:3055-3061，Kipriyanov等人(1999)，J.Mol.Biol.293:41-56和Roovers等人(2001)，Cancer Immunol.描述。
术语“CDR”是指抗体的可变结构域内主要促成抗原结合的6个高变区之一。通常，每个重链可变区中存在三个CDR(HCDR1、HCDR2、HCDR3)，每个轻链可变区中存在三个CDR(LCDR1、LCDR2、LCDR3)。可以使用各种公知方案中的任何一种来确定CDR的氨基酸序列边界，包括“Kabat”编号规则(参见Kabat等(1991)，“Sequences of Proteins of Immunological Interest”，第5版，Public Health Service，National Institutes of Health，Bethesda，MD)、“Chothia”编号规则(参见Al-Lazikani等人，(1997)JMB 273：927-948)和ImMunoGenTics(IMGT)编号规则(Lefranc M.P.，Immunologist，7，132-136(1999)；Lefranc，M.P.等，Dev.Comp.Immunol.，27，55-77(2003)等。例如，对于经典格式，遵循Kabat规则，所述重链可变域(VH)中的CDR氨基酸残基编号为31-35(HCDR1)、50-65(HCDR2)和95-102(HCDR3)；轻链可变域(VL)中的CDR氨基酸残基编号为24-34(LCDR1)、 50-56(LCDR2)和89-97(LCDR3)。遵循Chothia规则，VH中的CDR氨基酸编号为26-32(HCDR1)、52-56(HCDR2)和95-102(HCDR3)；并且VL中的氨基酸残基编号为26-32(LCDR1)、50-52(LCDR2)和91-96(LCDR3)。通过组合Kabat和Chothia两者的CDR定义，CDR由人VH中的氨基酸残基26-35(HCDR1)、50-65(HCDR2)和95-102(HCDR3)和人VL中的氨基酸残基24-34(LCDR1)、50-56(LCDR2)和89-97(LCDR3)构成。遵循IMGT规则，VH中的CDR氨基酸残基编号大致为26-35(CDR1)、51-57(CDR2)和93-102(CDR3)，VL中的CDR氨基酸残基编号大致为27-32(CDR1)、50-52(CDR2)和89-97(CDR3)。遵循IMGT规则，抗体的CDR区可以使用程序IMGT/DomainGap Align确定。
术语“框架区”，是指可变结构域VL或VH的一部分，其用作该可变结构域的抗原结合环(CDR)的支架。从本质上讲，其是不具有CDR的可变结构域。
术语“表位”或“抗原决定簇”是指抗原上被免疫球蛋白或抗体结合的部位。表位通常以独特的空间构象包括至少3、4、5、6、7、8、9、10、11、12、13、14或15个连续或非连续的氨基酸。参见，例如，Epitope Mapping Protocols in Methods in Molecular B iology，第66卷，G.E.Morris，Ed.(1996)。
术语“特异性结合”、“选择性结合”、“选择性地结合”和“特异性地结合”是指抗体或其片段对预先确定的抗原上的表位的结合。通常，抗体或其片段以大约小于10 -7M，例如大约小于10 -8M、10 -9M或10 -10M或更小的亲和力(KD)结合。
术语“KD”是指抗体-抗原相互作用的解离平衡常数。通常，本公开的抗体或抗原结合片段以小于大约10 -7M，例如小于大约10 -8M或10 -9M的解离平衡常数(KD)结合TROP-2或其表位，例如，在本公开中抗体与细胞表面抗原的亲和力采用FACS法测定KD值。
术语“核酸分子”是指DNA分子或RNA分子。核酸分子可以是单链或双链的，但优选是双链DNA。当将核酸与另一个核酸序列置于功能关系中时，核酸是“有效连接的”。例如，如果启动子或增强子影响编码序列的转录，那么启动子或增强子有效地连接至所述编码序列。
氨基酸序列“同一性”指比对氨基酸序列过程中，在必要时引入间隙，以达成最大序列同一性百分比，且不将任何保守性取代视为序列同一性的一部分，第一序列中与第二序列中的氨基酸残基相同的氨基酸残基的百分比。为测定氨基酸序列同一性百分比的目的，比对可以通过属于本领域技术的范围内的多种方式来实现，例如使用公开可得到的计算机软件，诸如BLAST、BLAST-2、ALIGN、ALIGN-2或Megalign(DNASTAR)软件。本领域技术人员可确定适用于测量比对的参数，包括在所比较的序列全长上达成最大比对所需的任何算法。
术语“表达载体”是指能够运输已与其连接的另一个核酸的核酸分子。在一个实施方案中，载体是“质粒”，其是指可将另外的DNA区段连接至其中的环 状双链DNA环。在另一个实施方案中，载体是病毒载体，其中可将另外的DNA区段连接至病毒基因组中。本文中公开的载体能够在已引入它们的宿主细胞中自主复制(例如，具有细菌的复制起点的细菌载体和附加型哺乳动物载体)或可在引入宿主细胞后整合入宿主细胞的基因组，从而随宿主基因组一起复制(例如，非附加型哺乳动物载体)。
现有技术中熟知生产和纯化抗体和抗原结合片段的方法，如冷泉港的抗体实验技术指南，5-8章和15章。发明所述的抗体或抗原结合片段用基因工程方法在非人源的CDR区加上一个或多个人源FR区。人FR种系序列可以通过比对IMGT人类抗体可变区种系基因数据库和MOE软件，从ImMunoGeneTics(IMGT)的网站得到，或者从免疫球蛋白杂志，Lefranc,G.,The Immunoglobulin FactsBook,Academic Press，2001ISBN012441351上获得。
术语“宿主细胞”是指已向其中引入了表达载体的细胞。宿主细胞可包括微生物(如细菌)、植物或动物细胞。易于转化的细菌包括肠杆菌科(enterobacteriaceae)的成员，例如大肠杆菌(Escherichia coli)或沙门氏菌(Salmonella)的菌株；芽孢杆菌科(Bacillaceae)例如枯草芽孢杆菌(Bacillus subtilis)；肺炎球菌(Pneumococcus)；链球菌(Streptococcus)和流感嗜血菌(Haemophilus influenzae)。适当的微生物包括酿酒酵母(Saccharomyces cerevisiae)和毕赤酵母(Pichia pastoris)。适当的动物宿主细胞系包括CHO(中国仓鼠卵巢细胞系)和NS0细胞。
本公开工程化的抗体或抗原结合片段可用常规方法制备和纯化。比如，编码重链和轻链的cDNA序列，可以克隆并重组至表达载体。重组的免疫球蛋白表达载体可以稳定地转染宿主细胞。作为一种更推荐的现有技术，哺乳动物类表达系统会导致抗体的糖基化，特别是在Fc区的N端位点。阳性的克隆在生物反应器的培养基中扩大培养以生产抗体。分泌了抗体的培养液可以用常规技术纯化。比如，用A或G Sepharose FF柱进行纯化。洗去非特异性结合的组分。再用pH梯度法洗脱结合的抗体，用SDS-PAGE检测抗体片段，收集。抗体可用常规方法进行过滤浓缩。可溶的混合物和多聚体，也可以用常规方法去除，比如分子筛、离子交换。得到的产物需立即冷冻，如-70℃，或者冻干。
术语“肽”是指由2个或2个以上氨基酸分子通过肽键相互连接而成的分子，是蛋白质的结构与功能片段。
术语“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个(例如1、2、3、4、5、6、7、8、9、10、11和12个)碳原子的烷基，更优选含有1至10个碳原子的烷基，最优选含有1至6个碳原子(包含1个、2个、3个、4个、5个或6个碳原子)的烷基。非限制性示例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲 基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基，及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基，非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基。
术语“杂烷基”指含有一个或多个选自N、O或S的杂原子的烷基，其中烷基如上所定义。
术语“亚烷基”指饱和的直链或支链脂肪族烃基，其具有从母体烷的相同碳原子或两个不同的碳原子上除去两个氢原子所衍生的残基，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个(例如1、2、3、4、5、6、7、8、9、10、11和12个)碳原子，更优选含有1至6个碳原子(包含1个、2个、3个、4个、5个或6个碳原子)的亚烷基。亚烷基的非限制性示例包括但不限于亚甲基(-CH 2-)、1,1-亚乙基(-CH(CH 3)-)、1,2-亚乙基(-CH 2CH 2)-、1,1-亚丙基(-CH(CH 2CH 3)-)、1,2-亚丙基(-CH 2CH(CH 3)-)、1,3-亚丙基(-CH 2CH 2CH 2-)、1,4-亚丁基(-CH 2CH 2CH 2CH 2-)和1,5-亚丁基(-CH 2CH 2CH 2CH 2CH 2-)等。亚烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选独立地任选选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基和氧代基中的一个或多个取代基所取代。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基)，其中烷基或环烷基的定义如上所述。烷氧基的非限制性示例包括：甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、 杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“卤代烷基”指烷基上的氢被一个或多个卤素取代，其中烷基如上所定义。
术语“氘代烷基”指烷基上的氢被一个或多个氘原子取代，其中烷基如上所定义。
术语“羟烷基”指烷基上的氢被一个或多个羟基取代，其中烷基如上所定义。
术语“羟基”指-OH基团。
术语“卤素”指氟、氯、溴或碘。
术语“氨基”指-NH 2。
术语“硝基”指-NO 2。
术语“氰基”指-CN。
本公开还包括各种氘化形式的式(Pc-L-Y-D)化合物。与碳原子连接的各个可用的氢原子可独立地被氘原子替换。本领域技术人员能够参考相关文献合成氘化形式的式(Pc-L-Y-D)化合物。在制备氘代形式的式(Pc-L-Y-D)化合物时可使用市售的氘代起始物质，或它们可使用常规技术采用氘代试剂合成，氘代试剂包括但不限于氘代硼烷、三氘代硼烷四氢呋喃溶液、氘代氢化锂铝、氘代碘乙烷和氘代碘甲烷等。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生地场合。例如，“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在，该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子，优选为最多5个，更优选为1个、2个或3个氢原子彼此独立地被取代基取代。取代基仅处在它们的可能的化学位置，本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如，具有游离氢的氨基或羟基与具有不饱和(如烯)键的碳原子结合时可能是不稳定的。
术语“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物，以及其他组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药，利于活性成分的吸收进而发挥生物活性。
术语“药学上可接受的盐”或“可药用盐”是指本公开抗体-药物偶联物的盐，这类盐用于受试者时具有安全性和有效性，且具有应有的生物活性，本公开配体药物偶联物至少含有一个氨基，因此可以与酸形成盐，可药用盐的非限制性示例包括：盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、硫酸氢盐、柠檬酸盐、乙酸盐、琥珀酸盐、抗坏血酸盐、草酸盐、硝酸盐、梨酸盐、磷酸氢盐、磷酸二氢盐、水杨酸盐、柠檬酸氢盐、酒石酸盐、马来酸盐、富马酸盐、甲酸盐、苯甲酸盐、甲 磺酸盐、乙磺酸盐、苯磺酸盐、对甲苯磺酸盐。
术语“载药量”或“平均药物载荷”是指配体-药物偶联物中每个配体上加载的细胞毒性药物平均数量，也可以表示为药物量和抗体量的比值，药物载量的范围可以是每个配体(Pc)连接0-12个，优选1-10个细胞毒性药物。在本公开的实施方案中，载药量表示为n，也可称为DAR(Drug-antibody Ratio)值，示例性的为1、2、3、4、5、6、7、8、9、10的平均值。可用常规方法如UV/可见光光谱法、质谱、ELISA试验和HPLC特征鉴定偶联反应后每个ADC分子的药物品均数量。
本公开的一个实施方式中，细胞毒性药物通过连接单元偶联在抗体的巯基上。
可以用以下非限制性方法控制配体-药物偶联物的载量，包括：
(1)控制连接试剂和单抗的摩尔比，
(2)控制反应时间和温度，
(3)选择不同的反应试剂。
常规的药物组合物的制备见中国药典。
术语“载体”用于本公开的药物，是指能改变药物进入人体的方式和在体内的分布、控制药物的释放速度并将药物输送到靶向器官的体系。药物载体释放和靶向系统能够减少药物降解及损失，降低副作用，提高生物利用度。如可作为载体的高分子表面活性剂由于其独特的两亲性结构，可以进行自组装，形成各种形式的聚集体，优选的示例如胶束、微乳液、凝胶、液晶、囊泡等。这些聚集体具有包载药物分子的能力，同时又对膜有良好的渗透性，可以作为优良的药物载体。
术语“赋形剂”是在药物制剂中除主药以外的附加物，也可称为辅料。如片剂中的粘合剂、填充剂、崩解剂、润滑剂；半固体制剂软膏剂、霜剂中的基质部分；液体制剂中的防腐剂、抗氧剂、矫味剂、芳香剂、助溶剂、乳化剂、增溶剂、渗透压调节剂、着色剂等均可称为赋形剂。
术语“稀释剂”又称填充剂，其主要用途是增加片剂的重量和体积。稀释剂的加入不仅保证一定的体积大小，而且减少主要成分的剂量偏差，改善药物的压缩成型性等。当片剂的药物含有油性组分时，需加入吸收剂吸收油性物，使保持“干燥”状态，以利于制成片剂。如淀粉、乳糖、钙的无机盐、微晶纤维素等。
药物组合物可以是无菌注射水溶液形式。可在使用的可接受的溶媒和溶剂中有水、林格氏液和等渗氯化钠溶液。无菌注射制剂可以是其中活性成分溶于油相的无菌注射水包油微乳。例如将活性成分溶于大豆油和卵磷脂的混合物中。然后将油溶液加入水和甘油的混合物中处理形成微乳。可通过局部大量注射，将注射液或微乳注入受试者的血流中。或者，最好按可保持本公开化合物恒定循环浓度的方式给予溶液和微乳。为保持这种恒定浓度，可使用连续静脉内递药装置。这种装置的示例是Deltec CADD-PLUS.TM.5400型静脉注射泵。
药物组合物可以是用于肌内和皮下给药的无菌注射水或油混悬液的形式。可 按已知技术，用上述那些适宜的分散剂或湿润剂和悬浮剂配制该混悬液。无菌注射制剂也可以是在无毒肠胃外可接受的稀释剂或溶剂中制备的无菌注射溶液或混悬液，例如1,3-丁二醇中制备的溶液。此外，可方便地用无菌固定油作为溶剂或悬浮介质。为此目的，可使用包括合成甘油单或二酯在内的任何调和固定油。此外，脂肪酸例如油酸也可以制备注射剂。
二、合成方法
为了完成合成目的，采用如下的合成技术方案：
通式(Pc-L a-Y-D)所示的化合物的制备方法，其包括如下步骤：
Figure PCTCN2021073279-appb-000015
Pc还原后，与通式(L a-Y-D)偶联反应，得到通式(Pc-L a-Y-D)所示的化合物；还原剂优选TCEP，特别地，优选还原抗体上的二硫键；
其中：
Pc、W、L 2、L 3、R 1、R 2、R 5、R 6、R 7、m和n如前述通式(Pc-L a-Y-D)中所定义。
在以上说明书中提出了本公开一种或多种实施方案的细节。虽然可使用与本文所述类似或相同的任何方法和材料来实施或测试本公开，但是以下描述优选的方法和材料。通过说明书和权利要求书，本公开的其他特点、目的和优点将是显而易见的。在说明书和权利要求书中，除非上下文中有清楚的另外指明，单数形式包括复数指代物的情况。除非另有定义，本文使用的所有技术和科学术语都具有本公开所属领域普通技术人员所理解的一般含义。说明书中引用的所有专利和出版物都通过引用纳入。提出以下实施例是为了更全面地说明本公开的优选实施方案。这些实施例不应以任何方式理解为限制本公开的范围，本公开的范围由权利要求书限定。
实施例
本发明实施例或测试例中未注明具体条件的实验方法，通常按照常规条件，或按照原料或商品制造厂商所建议的条件。参见Sambrook等，分子克隆，实验室手册，冷泉港实验室；当代分子生物学方法，Ausubel等著，Greene出版协会，Wiley Interscience，NY。未注明具体来源的试剂，为市场购买的常规试剂。
一、抗体的制备
实施例1-1：TROP-2高表达细胞株构建
将pCDH-hTROP-2慢病毒表达载体质粒与pVSV-G，pCMV-dR8.91慢病毒系统包装载体用Lipofectamine 3000转染试剂转染至病毒包装细胞293T中，收集含有病毒的培养基上清，过滤并进行超高速离心，使用浓缩后的病毒感染中国仓鼠卵巢细胞CHO-K1，经嘌呤霉素(puromycin)筛选两至三周，再进行FACS单细胞分选。
通过FACS检测慢病毒感染的CHO-K1细胞表面的TROP-2表达量，挑选出TROP-2表达量高的CHO-K1/hTROP-2单克隆细胞株。
TROP-2氨基酸序列(Genbank:NP_002344.2)如下：
Figure PCTCN2021073279-appb-000016
Trop2-His氨基酸序列：
Figure PCTCN2021073279-appb-000017
实施例1-2：抗人TROP-2单克隆抗体的制备
本申请中的抗人TROP-2单克隆抗体依照WO03074566专利中公开的方法制备，以hRS7的抗体可变区基因为模板利用计算机软件针对CDR进行点突变改造设计。通过分子克隆插入至蛋白表达载体Phr-IgG(带信号肽及恒定区基因(CH1-Fc/CL)片段))中，在HEK293和Expi-CHO-S细胞中进行表达。按照常规 方法进行抗体纯化。利用过表达huTROP-2蛋白的CHO-K1细胞和huTROP-2蛋白(His27-Thr274登录号#NP_002344.2)进行活性验证，挑选出靶点结合活性较好的抗体，其中PD3可变区序列如下：
PD3重链可变区：
Figure PCTCN2021073279-appb-000018
PD3轻链可变区：
Figure PCTCN2021073279-appb-000019
注：下划线部分为依照Kabat编号规则确定的CDR区。
表1.PD3抗体的CDR区
抗体 PD3
重链CDR1 NYGMN(SEQ ID NO：5)
重链CDR2 WINTYTGEPTYTQDFKG(SEQ ID NO：6)
重链CDR3 GGFGSSYWYFDV(SEQ ID NO：7)
轻链CDR1 KASQDVSIAVA(SEQ ID NO：8)
轻链CDR2 SASYRYT(SEQ ID NO：9)
轻链CDR3 QQHYITPLT(SEQ ID NO：10)
抗体的重链恒定区可选自人IgG1、IgG2、IgG4及其变体的恒定区，轻链恒定区可选自人源κ、λ链或其变体的轻链恒定区。示例性的，抗体重链恒定区选自序列如SEQ ID NO：11所示的人IgG1，轻链恒定区选自序列如SEQ ID NO：12所示的人κ链的恒定区。
人IgG1的重链恒定区：
Figure PCTCN2021073279-appb-000020
人源κ轻链恒定区：
Figure PCTCN2021073279-appb-000021
示例性地，将上述轻链/重链恒定区与前述PD3抗体的可变区组合形成完整的抗体，其轻链/重链序列如下：
PD3重链：
Figure PCTCN2021073279-appb-000022
PD3轻链：
Figure PCTCN2021073279-appb-000023
本公开中使用的对照分子hRS7参照专利WO03074566构建，TINA抗体参照专利WO2015098099A1构建，其序列分别如下：
hRS7重链：
Figure PCTCN2021073279-appb-000024
hRS7轻链：
Figure PCTCN2021073279-appb-000025
TINA重链：
Figure PCTCN2021073279-appb-000026
TINA轻链：
Figure PCTCN2021073279-appb-000027
二、化合物的制备
本公开实施例中未注明具体条件的实验方法，通常按照常规条件，或按照原料或商品制造厂商所建议的条件。未注明具体来源的试剂，为市场购买的常规试剂。
化合物的结构是通过核磁共振(NMR)或质谱(MS)来确定的。NMR的测定是用Bruker AVANCE-400核磁仪，测定溶剂为氘代二甲基亚砜(DMSO-d6)、氘代氯仿(CDCl 3)、氘代甲醇(CD 3OD)，内标为四甲基硅烷(TMS)，化学位移是以10 -6(ppm)作为单位给出。
MS的测定用FINNIGAN LCQAd(ESI)质谱仪(生产商：Thermo,型号：Finnigan LCQ advantage MAX)。
UPLC的测定用Waters Acquity UPLC SQD液质联用仪。
HPLC的测定使用安捷伦1200DAD高压液相色谱仪(Sunfire C18 150×4.6mm色谱柱)和Waters 2695-2996高压液相色谱仪(Gimini C18 150×4.6mm色谱柱)。
UV-HPLC的测定使用Thermo nanodrop2000紫外分光光度计。
增殖抑制率及IC 50值的测定用PHERA starFS酶标仪(德国BMG公司)。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板，薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm至0.2mm，薄层层析分离纯化产品采用的规格是0.4mm至0.5mm硅胶板。
柱层析一般使用烟台黄海200～300目硅胶为载体。
本公开的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买自ABCR GmbH & Co.KG，Acros Organnics，Aldrich Chemical Company，韶远化学科技(Accela ChemBio Inc)、达瑞化学品等公司。
实施例中如无特殊说明，反应均在氩气氛或氮气氛下进行。
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气或氮气气球。
氢气氛是指反应瓶连接一个约1L容积的氢气气球。
加压氢化反应使用Parr 3916EKX型氢化仪和清蓝QL-500型氢气发生器或HC2-SS型氢化仪。
氢化反应通常抽真空，充入氢气，反复操作3次。
微波反应使用CEM Discover-S 908860型微波反应器。
实施例中如无特殊说明，反应中的溶液是指水溶液。
实施例中如无特殊说明，反应的温度为室温。
室温为最适宜的反应温度，温度范围是20℃至30℃。
实施例中pH＝6.5的PBS缓冲液的配制：取KH 2PO 4 8.5g，K 2HPO 4.3H 2O 8.56g，NaCl 5.85g，EDTA 1.5g置于瓶中，定容至2L，超声波使其全部溶解，摇匀即得。
纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂的体系包括：A：二氯甲烷和异丙醇体系，B：二氯甲烷和甲醇体系，C：石油醚和乙酸乙酯体系，溶剂的体积比根据化合物的极性不同而进行调节，也可以加入少量的三乙胺和酸性或碱性试剂等进行调节。
本公开部分化合物是通过Q-TOF LC/MS来表征的。Q-TOF LC/MS使用安捷伦6530精确质量数四级杆-飞行时间质谱仪和安捷伦1290-Infinity超高效液相色谱仪(安捷伦Poroshell 300SB-C8 5μm,2.1×75mm色谱柱)。
本公开抗体-药物偶联物的Y-D药物部分参见PCT/CN2019/107873，相关的化合物合成及测试引用至本专利。其中的非限制性实施例合成引用如下：
实施例2-1
N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-1-羟基环丙烷-1-甲酰胺1
Figure PCTCN2021073279-appb-000028
Figure PCTCN2021073279-appb-000029
向依喜替康甲磺酸盐1b(2.0mg，3.76μmol，采用专利申请“EP0737686A1”公开的方法制备而得)中添加1mL N,N-二甲基甲酰胺，冰水浴冷却至0-5℃，滴加一滴三乙胺，搅拌至反应液变澄清。向反应液中依次加入1-羟基环丙基甲酸1a(1.4mg，3.7μmol，采用公知的方法“Tetrahedron Letters,25(12),1269-72；1984”制备而得)和4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(3.8mg，13.7μmol)，加毕，在0-5℃搅拌反应2小时。向反应液中加入5mL水淬灭反应，用乙酸乙酯(8mL×3)萃取反应液，合并有机相，用饱和氯化钠溶液(5mL×2)洗涤，有机相用无水硫酸钠干燥，过滤，将滤液减压浓缩，用薄层层析以展开剂体系B纯化所得残余物，得到标题产物1(1.6mg，产率：82.1％)。
MS m/z(ESI):520.2[M+1]
1H NMR(400MHz,CDCl 3):δ7.90-7.84(m,1H),7.80-7.68(m,1H),5.80-5.70(m,1H),5.62-5.54(m,2H),5.44-5.32(m,2H),5.28-5.10(m,2H),3.40-3.15(m,3H),2.44(s,3H),2.23(t,1H),2.06-1.75(m,2H),1.68-1.56(m,1H),1.22-1.18(m,2H),1.04-0.98(m,2H),0.89(t,3H)。
实施例2-2
(S)-2-环丙基-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-2-羟基乙酰胺2-A(R)-2-环丙基-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-2-羟基乙酰胺2-B
Figure PCTCN2021073279-appb-000030
向1b(4mg，7.53μmol)中加入2mL乙醇和0.4mL N,N-二甲基甲酰胺，氩气置换三次，冰水浴冷却至0-5℃，滴加0.3mL N-甲基吗啉，搅拌至反应液变澄清。向反应液中依次加入2-环丙基-2-羟基乙酸2a(2.3mg，19.8μmol，采用专利申请“WO2013106717”公开的方法制备而得)、1-羟基苯并三唑(3mg，22.4μmol)和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(4.3mg，22.4μmol)，加毕，在0-5℃搅拌反应1小时。撤去冰水浴，加热至30℃搅拌2小时。反应液减压浓缩，所得到的粗品化合物2用高效液相色谱法纯化(分离条件：色谱柱：XBridge Prep C18 OBD 5um 19*250mm；流动相：A-水(10mmol NH 4OAc)，B-乙腈，梯度洗脱，流速：18mL/min)，收集其相应组分，减压浓缩，得到标题产物(2-A：1.5mg，2-B：1.5mg)。
MS m/z(ESI):534.0[M+1]。
单一构型化合物2-B(较短保留时间)
UPLC分析：保留时间1.06分钟，纯度：88％(色谱柱：ACQUITY UPLC BEHC18 1.7um 2.1*50mm，流动相：A-水(5mmol NH 4OAc),B-乙腈)。
1H NMR(400MHz,DMSO-d 6):δ8.37(d,1H),7.76(d,1H),7.30(s,1H),6.51(s,1H),5.58-5.56(m,1H),5.48(d,1H),5.41(s,2H),5.32-5.29(m,2H),3.60(t,1H),3.19-3.13(m,1H),2.38(s,3H),2.20-2.14(m,1H),1.98(q,2H),1.87-1.83(m,1H),1.50-1.40(m,1H),1.34-1.28(m,1H),0.86(t,3H),0.50-0.39(m,4H)。
单一构型化合物2-A(较长保留时间)
UPLC分析：保留时间1.10分钟，纯度：86％(色谱柱：ACQUITY UPLC BEHC18 1.7um 2.1*50mm，流动相：A-水(5mmol NH 4OAc),B-乙腈)。
1H NMR(400MHz,DMSO-d 6):δ8.35(d,1H),7.78(d,1H),7.31(s,1H),6.52(s,1H),5.58-5.53(m,1H),5.42(s,2H),5.37(d,1H),5.32(t,1H),3.62(t,1H),3.20-3.15(m,2H),2.40(s,3H),2.25-2.16(m,1H),1.98(q,2H),1.87-1.82(m,1H),1.50-1.40(m,1H),1.21-1.14(m,1H),0.87(t,3H),0.47-0.35(m,4H)。
实施例2-3
(S)-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-3,3,3-三氟-2-羟基丙酰胺3-A
(R)-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-3,3,3-三氟-2-羟基丙酰胺3-B
Figure PCTCN2021073279-appb-000031
向1b(5.0mg，9.41μmol)中添加2mL乙醇和0.4mL N,N-二甲基甲酰胺，冰水浴冷却至0-5℃，滴加0.3mL N-甲基吗啡啉，搅拌至反应液变澄清。向反应液中依次加入3,3,3-三氟-2-羟基丙酸3a(4.1mg，28.4μmol，供应商Alfa)、1-羟基苯并三唑(3.8mg，28.1μmol)和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(5.4mg，28.2μmol)，加毕，在0-5℃搅拌反应10分钟。撤去冰水浴，加热至30℃搅拌8小时。反应液减压浓缩，所得到的粗品化合物3用高效液相色谱法纯化(分离条件：色谱柱：XBridge Prep C18 OBD 5um 19*250mm；流动相：A-水(10mmol NH 4OAc)：B-乙腈，梯度洗脱，流速：18mL/min)，收集其相应组分，减压浓缩，得到标题产物(1.5mg，1.5mg)。
MS m/z(ESI):561.9[M+1]。
单一构型化合物(较短保留时间)
UPLC分析：保留时间1.11分钟，纯度：88％(色谱柱：ACQUITY UPLC BEHC18 1.7um 2.1*50mm，流动相：A-水(5mmol NH 4OAc),B-乙腈)。
1H NMR(400MHz,DMSO-d 6):δ8.94(d,1H),7.80(d,1H),7.32(s,1H),7.20(d,1H),6.53(s,1H),5.61-5.55(m,1H),5.45-5.23(m,3H),5.15-5.06(m,1H),4.66-4.57(m,1H),3.18-3.12(m,1H),2.40(s,3H),2.26-2.20(m,1H),2.16-2.08(m,1H),2.02-1.94(m,1H),1.89-1.82(m,1H),1.50-1.40(m,1H),0.87(t,3H)。
单一构型化合物(较长保留时间)
UPLC分析：保留时间1.19分钟，纯度：90％(色谱柱：ACQUITY UPLC BEHC18 1.7um 2.1*50mm，流动相：A-水(5mmol NH 4OAc),B-乙腈)。
1H NMR(400MHz,DMSO-d 6):δ8.97(d,1H),7.80(d,1H),7.31(s,1H),7.16(d,1H),6.53(s,1H),5.63-5.55(m,1H),5.45-5.20(m,3H),5.16-5.07(m,1H),4.66-4.57(m,1H),3.18-3.12(m,1H),2.40(s,3H),2.22-2.14(m,1H),2.04-1.95(m,2H),1.89-1.82(m,1H),1.50-1.40(m,1H),0.87(t,3H)。
实施例2-4
N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-1-羟基环戊烷-1-甲酰胺4
Figure PCTCN2021073279-appb-000032
向1b(3.0mg，5.64μmol)中添加1mL N,N-二甲基甲酰胺，冰水浴冷却至0-5℃，滴加一滴三乙胺，搅拌至反应液变澄清。向反应液中依次加入1-羟基-环戊烷甲酸4a(2.2mg，16.9μmol，采用专利申请“WO2013106717”公开的方法制备而得)和4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(4.7mg，16.9μmol)，加毕，在0-5℃搅拌反应1小时。向反应液中加入5mL水淬灭反应，用乙酸乙酯(10mL×3)萃取反应液，合并有机相，用饱和氯化钠溶液(5mL×2)洗涤，有机相用无水硫酸钠干燥，过滤，将滤液减压浓缩，用薄层层析以展开剂体系B纯化所得残余物，得到标题产物4(2.5mg，产率：80.9％)。
MS m/z(ESI):548.0[M+1]。
1H NMR(400MHz,CDCl 3):δ7.73-7.62(m,2H),5.75-5.62(m,1H),5.46-5.32(m,2H),5.26-5.10(m,1H),3.30-3.10(m,1H),2.43(s,3H),2.28-2.20(m,2H),2.08-1.84(m,8H),1.69-1.58(m,2H),1.04-1.00(m,2H),0.89(t,3H)。
实施例2-5
N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-1-(羟甲基)环丙烷-1-甲酰胺5
Figure PCTCN2021073279-appb-000033
向1b(2.0mg，3.76μmol)中添加1mL N,N-二甲基甲酰胺，冰水浴冷却至0-5℃，滴加一滴三乙胺，搅拌至反应液变澄清。向反应液中依次加入1-(羟甲基)-环戊烷甲酸5a(0.87mg，7.5μmol，采用专利申请“WO201396771”公开的方法制备而得)和4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(2mg，7.24μmol)，加毕，在0-5℃搅拌反应2小时。向反应液中加入5mL水淬灭反应，用乙酸乙酯(8mL×3)萃取反应液，合并有机相，用饱和氯化钠溶液(5mL×2)洗涤，有机相用无水硫酸钠干燥，过滤，将滤液减压浓缩，用薄层层析以展开剂体系B纯化所得残余物，得到标题产物5(1.0mg，产率：50％)。
MS m/z(ESI):533.9[M+1]。
1H NMR(400MHz,CDCl 3):δ8.07(s,1H),7.23-7.18(m,2H),6.71-6.64(m,1H),6.55-6.51(m,1H),5.36-5.27(m,2H),4.67-4.61(m,2H),3.53-3.48(m,1H),3.30-3.22(m,2H),3.18-3.13(m,1H),2.71-2.61(m,2H),2.35-2.28(m,1H),2.04-1.91(m,4H),1.53-1.40(m,3H),0.91-0.75(m,4H)。
实施例2-6
N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-1-(羟基甲基)环丁烷-1-甲酰胺6
Figure PCTCN2021073279-appb-000034
Figure PCTCN2021073279-appb-000035
向1b(3.0mg，5.64μmol)中添加1mL N,N-二甲基甲酰胺，冰水浴冷却至0-5℃，滴加一滴三乙胺，搅拌至反应液变澄清。向反应液中依次加入1-(羟基甲基)环丁烷-1-甲酸6a(2.2mg，16.9μmol；采用文献“Journal of the American Chemical Society,2014,vol.136,#22,p.8138-8142”公开的方法制备而得)和4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(4.7mg，16.9μmol)，加毕，在0-5℃搅拌反应1小时。向反应液中加入5mL水淬灭反应，用乙酸乙酯(10mL×3)萃取反应液，合并有机相，用饱和氯化钠溶液(5mL×2)洗涤，有机相用无水硫酸钠干燥，过滤，将滤液减压浓缩，用薄层层析以展开剂体系B纯化所得残余物，得到标题产物6(2.1mg，产率：67.9％)。
MS m/z(ESI):548.0[M+1]。
1H NMR(400MHz,DMSO-d 6):δ7.85-7.62(m,1H),6.88(br，1H),5.87-5.48(m，2H),5.47-5.33(m，1H),5.31-5.06(m，1H),4.25-3.91(m,2H),3.25(br,1H),2.60-2.32(m,3H),2.23(t,1H),2.15-1.95(m,3H),1.70-1.56(m,2H),1.41-1.17(m,9H),1.03(s,1H),0.95-0.80(m,2H)。
实施例2-7
N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)-1-羟基环丁烷-1-甲酰胺7
Figure PCTCN2021073279-appb-000036
Figure PCTCN2021073279-appb-000037
向1b(3.0mg，5.64μmol)中添加2mL乙醇和0.4mL N,N-二甲基甲酰胺，冰水浴冷却至0-5℃，滴加0.3mL N-甲基吗啡啉，搅拌至反应液变澄清。向反应液中依次加入1-羟基环丁烷甲酸7a(2.0mg，17.22μmol，供应商药石)，1-羟基苯并三唑(2.3mg，17.0μmol)和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(3.2mg，16.7μmol)，加毕，在0-5℃搅拌反应10分钟。撤去冰水浴，常温搅拌2小时。反应液减压浓缩，用薄层层析以展开剂体系B纯化所得残余物，得到标题产物7(2.5mg，产率：83.1％)。
MS m/z(ESI):534.0[M+1]。
1H NMR(400MHz,DMSO-d 6):δ8.28(d,1H),7.75(d,1H),7.29(s,1H),6.51(s,1H),6.12(s,1H),5.59-5.51(m,1H),5.41(s,2H),5.20-5.01(m,2H),3.27-3.17(m,1H),3.15-3.05(m,1H),2.71-2.63(m,1H),2.37(s,3H),2.12-2.05(m,1H),2.03-1.94(m,2H),1.92-1.78(m,4H),1.50-1.42(m,1H),0.90-0.83(m,4H)。
实施例2-8
1-(((S)-7-苄基-20-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-3,6,9,12,15-五氧代-2,5,8,11,14-五氮杂二十烷基)氧基)-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)环丙烷-1-甲酰胺8
Figure PCTCN2021073279-appb-000038
Figure PCTCN2021073279-appb-000039
第一步
1-((2-((((9H-芴-9-基)甲氧基)羰基)氨基)乙酰氨基)甲氧基)环丙烷-1-羧酸苄酯8c
将1-羟基环丙烷-1-羧酸苄酯8a(104mg，0.54mmol；采用专利申请“US2005/20645”公开的方法制备而得)和2-((((9H-芴-9-基)甲氧基)羰基)氨基)乙酰氨基)甲基乙酸酯8b(100mg，0.27mmol；采用专利申请“CN105829346A”公开的方法制备而得)加入反应瓶，加入5mL四氢呋喃，氩气置换三次，冰水浴降温至0-5℃，加入叔丁醇钾(61mg，0.54mmol)，撤去冰浴，升至室温搅拌10分钟，加入20mL冰水，用乙酸乙酯(5mL×2)和氯仿(5mL×5)萃取，合并有机相并浓缩。所得残余物溶于3mL 1,4-二氧六环中，加入0.6mL水，加入碳酸氢钠(27mg，0.32mmol)和氯甲酸-9-芴甲酯(70mg，0.27mmol)，室温搅拌1小时。加入20mL水，用乙酸乙酯(8mL×3)萃取，有机相用饱和氯化钠溶液(20mL)洗涤，无水硫酸钠干燥，过滤，滤液减压浓缩，用硅胶柱色谱法以展开剂体系B纯化所得残余物，得到标题产物8c(100mg，产率：73.6％)。
MS m/z(ESI):501.0[M+1]。
第二步
1-((2-((((9H-芴-9-基)甲氧基)羰基)氨基)乙酰氨基)甲氧基)环丙烷-1-羧酸8d
将8c(50mg，0.10mmol)溶于3mL四氢呋喃和乙酸乙酯(V:V＝2:1)混合溶剂中，加入钯碳(25mg，含量10％)，氢气置换三次，室温搅拌反应1小时。反应液用硅藻土过滤，滤饼用四氢呋喃淋洗，滤液浓缩，得到标题产物8d(41mg，产率：100％)。
MS m/z(ESI):411.0[M+1]。
第三步
(9H-芴-9-基)甲基(2-(((1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基羰基)环丙氧基)甲基)氨基)-2-氧代乙基)氨基甲酸酯8e
将1b(7mg，0.013mmol)加入反应瓶，加入1mL N,N-二甲基甲酰胺，氩气置换三次，冰水浴降温至0-5℃，滴加一滴三乙胺，加入8d(7mg，0.017mmol)的0.5mL N,N-二甲基甲酰胺溶液，加入4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(7mg，0.026mmol)，冰浴搅拌反应35分钟。加入10mL水，用乙酸乙酯(5mL×3)萃取，有机相用饱和氯化钠溶液(10mL)洗涤，无水硫酸钠干燥，过滤，滤液减压浓缩，用薄层层析以展开剂体系B纯化所得残余物，得到标题产物8e(8.5mg，产率78.0％)。
MS m/z(ESI):828.0[M+1]。
第四步
1-((2-氨基乙酰氨基)甲氧基)-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)环丙烷-1-甲酰胺8f
将8e(4mg，4.84μmol)溶于0.2mL二氯甲烷中，加入0.1mL二乙胺，室温搅拌2小时。反应液减压浓缩，加入2mL甲苯减压浓缩，重复两次，加入3mL正己烷打浆，倾倒出上层正己烷，重复三次，减压浓缩得到粗品标题产物8f(2.9mg)，产品不经纯化直接用于下一步反应。
MS m/z(ESI):606.0[M+1]。
第五步
1-(((S)-7-苄基-20-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-3,6,9,12,15-五氧代-2,5,8,11,14-五氮杂二十烷基)氧基)-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)环丙烷-1-甲酰胺8
将粗品8f(2.9mg，4.84μmol)溶于0.5mL N,N-二甲基甲酰胺，氩气置换三次，冰水浴降温至0-5℃，加入(S)-2(-2-(-2-(6-(2,5-二氧代-1H-吡咯-1-基)已酰氨基)乙酰氨基)乙酰氨基)-3-苯基丙酸8g(2.7mg，5.80μmol，采用专利申请“EP2907824”公开的方法制备而得)的0.3mL N,N-二甲基甲酰胺溶液，加入4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(2.7mg，9.67μmol)，冰浴搅拌反应30分钟，撤去冰浴，升至室温搅拌15分钟。反应液进行高效液相色谱法纯化(分离条件：色谱柱：XBridge Prep C18 OBD 5um 19*250mm；流动相:A-水(10mmol NH 4OAc)：B-乙腈，梯度洗脱，流速：18mL/min)，收集其相应组分，减压浓缩得到标题产物8(2mg，产率：39.0％)。
MS m/z(ESI):1060.0[M+1]。
1H NMR(400MHz,DMSO-d 6):δ9.01(d,1H),8.77(t,1H),8.21(t,1H),8.08-7.92(m,2H),7.73(d,1H),7.28(s,1H),7.24-7.07(m,4H),6.98(s,1H),6.50(s,1H),5.61(q,1H),5.40(s,2H),5.32(t,1H),5.12(q,2H),4.62(t,1H),4.52(t,1H),4.40-4.32(m,1H),3.73-3.47(m,8H),3.16-3.04(m,2H),2.89(dd,1H),2.69-2.55(m,2H),2.37-2.23(m,4H),2.12-1.93(m,4H),1.90-1.74(m,2H),1.52-1.38(m,4H), 1.33-1.11(m,5H),0.91-0.81(m,4H)。
实施例2-9
N-((2R,10S)-10-苄基-2-环丙基-1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-1,6,9,12,15-五氧代-3-氧杂-5,8,11,14-四氮杂十六-16-基)-6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺9-A
N-((2S,10S)-10-苄基-2-环丙基-1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-1,6,9,12,15-五氧代-3-氧杂-5,8,11,14-四氮杂十六-16-基)-6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺9-B
Figure PCTCN2021073279-appb-000040
第一步
2-环丙基-2-羟基乙酸苄酯9a
将2a(1.3g，11.2mmol；采用专利申请“WO2013/106717”公开的方法制备而得)溶于50mL乙腈中，依次加入碳酸钾(6.18g，44.8mmol)，溴化苄(1.33mL，11.2mmol)和四丁基碘化铵(413mg，1.1mmol)。将反应液室温搅拌48小时，通过硅藻土过滤，滤饼用乙酸乙酯(10ml)淋洗，合并滤液减压浓缩，用硅胶柱色谱法以 展开剂体系C纯化所得残余物，得到标题产物9a(2g，产率：86.9％)。
第二步
10-环丙基-1-(9H-芴-9-基)-3,6-二氧代-2,9-二氧杂-4,7-二氮杂十一-11-酸苄酯9b
将9a(120.9mg,0.586mmol)和8b(180mg，0.489mmol)加入反应瓶，加入4mL四氢呋喃，氩气置换三次，冰水浴降温至0-5℃，加入叔丁醇钾(109mg，0.98mmol)，撤去冰浴，升至室温搅拌40分钟，加入10mL冰水，用乙酸乙酯(20mL×2)和氯仿(10mL×5)萃取，合并有机相并浓缩。所得残余物溶于4mL二氧六环中，加入2mL水，加入碳酸氢钠(49.2mg，0.586mmol)和氯甲酸-9-芴甲酯(126mg，0.49mmol)，室温搅拌2小时。加入20mL水，用乙酸乙酯(10mL×3)萃取，有机相用饱和氯化钠溶液(20mL)洗涤，无水硫酸钠干燥，过滤，滤液减压浓缩。用硅胶柱色谱法以展开剂体系C纯化所得残余物，得到标题产物9b(48mg，产率：19％)。
MS m/z(ESI):515.0[M+1]。
第三步
10-环丙基-1-(9H-芴-9-基)-3,6-二氧代-2,9-二氧杂-4,7-二氮杂十一-11-酸9c
将9b(20mg，0.038mmol)溶于4.5mL四氢呋喃和乙酸乙酯(V:V＝2:1)混合溶剂中，加入钯碳(12mg，含量10％，干型)，氢气置换三次，室温搅拌反应1小时。反应液用硅藻土过滤，滤饼用乙酸乙酯淋洗，滤液浓缩，得到粗品标题产物9c(13mg)，产品不经纯化直接进行下一步反应。
MS m/z(ESI):424.9[M+1]。
第四步
(9H-芴-9-基)甲基(2-(((1-环丙基-2-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-2-氧代乙氧基)甲基)氨基)-2-氧代乙基)氨基甲酸酯9d
将1b(10mg，18.8μmol)加入反应瓶，加入1mL N,N-二甲基甲酰胺，氩气置换三次，冰水浴降温至0-5℃，滴加一滴三乙胺，加入粗品9c(13mg，30.6μmol)，加入4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(16.9mg，61.2μmol)，冰浴搅拌反应40分钟。加入10mL水，用乙酸乙酯(10mL×3)萃取，合并有机相。有机相用饱和氯化钠溶液(10mL×2)洗涤，有机相用无水硫酸钠干燥，过滤，滤液减压浓缩。用薄层层析以展开剂体系B纯化所得残余物，得到标题产物9d(19mg，产率：73.6％)。
MS m/z(ESI):842.1[M+1]。
第五步
2-((2-氨基乙酰氨基)甲氧基)-2-环丙基-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)乙酰胺9e
将9d(19mg，22.6μmol)溶于2mL二氯甲烷中，加入1mL二乙胺，室温搅 拌2小时。反应液减压浓缩，加入1mL甲苯并减压浓缩，重复两次。往残余物中加入3mL正己烷打浆，静置后倾倒出上层清液，保留固体。将固体残余物减压浓缩，油泵拉干得到粗品标题产物9e(17mg)，产品不经纯化直接用于下一步反应。
MS m/z(ESI):638.0[M+18]。
第六步
N-((2R,10S)-10-苄基-2-环丙基-1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-1,6,9,12,15-五氧代-3-氧杂-5,8,11,14-四氮杂十六-16-基)-6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺9-A
N-((2S,10S)-10-苄基-2-环丙基-1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-1,6,9,12,15-五氧代-3-氧杂-5,8,11,14-四氮杂十六-16-基)-6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺9-B
将粗品9e(13.9mg，22.4μmol)溶于0.6mL N,N-二甲基甲酰胺，氩气置换三次，冰水浴降温至0-5℃，加入8g(21.2mg，44.8μmol)的0.3mL N,N-二甲基甲酰胺溶液，加入4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(18.5mg，67.3μmol)，冰浴搅拌反应10分钟，撤去冰浴，升至室温搅拌1小时，反应生成化合物9。反应液进行高效液相色谱法纯化(分离条件：色谱柱：XBridge Prep C18 OBD 5um 19*250mm；流动相:A-水(10mmol NH 4OAc)：B-乙腈，梯度洗脱，流速：18mL/min)，收集其相应组分，减压浓缩，得到标题产物(9-A：2.4mg，9-B：1.7mg)。
MS m/z(ESI):1074.4[M+1]。
单一构型化合物9-A(较短保留时间)：
UPLC分析:保留时间1.14分钟，纯度：85％(色谱柱：ACQUITY UPLC BEHC18 1.7um 2.1*50mm，流动相：A-水(5mmol NH 4OAc),B-乙腈)。
1H NMR(400MHz,DMSO-d 6):δ8.60(t,1H),8.51-8.49(d,1H),8.32-8.24(m,1H),8.13-8.02(m,2H),8.02-7.96(m,1H),7.82-7.75(m,1H),7.31(s,1H),7.26-7.15(m,4H),6.99(s,1H),6.55-6.48(m,1H),5.65-5.54(m,1H),5.41(s,2H),5.35-5.15(m,3H),4.74-4.62(m,1H),4.54-4.40(m,2H),3.76-3.64(m，4H),3.62-3.48(m,2H),3.20-3.07(m,2H),3.04-2.94(m,1H),2.80-2.62(m,1H),2.45-2.30(m,3H),2.25-2.15(m,2H),2.15-2.04(m,2H),1.93-1.78(m,2H),1.52-1.39(m,3H),1.34-1.12(m,5H),0.87(t,3H),0.64-0.38(m,4H)。
单一构型化合物9-B(较长保留时间)：
UPLC分析:保留时间1.16分钟，纯度：89％(色谱柱：ACQUITY UPLC BEHC18 1.7um 2.1*50mm，流动相：A-水(5mmol NH 4OAc),B-乙腈)。
1H NMR(400MHz,DMSO-d 6):δ8.68-8.60(m,1H),8.58-8.50(m,1H),8.32-8.24(m,1H),8.13-8.02(m,2H),8.02-7.94(m,1H),7.82-7.75(m,1H),7.31(s,1H),7.26-7.13(m,3H),6.99(s,1H),6.55-6.48(m,1H),5.60-5.50(m,1H),5.41(s,2H), 5.35-5.15(m,2H),4.78-4.68(m,1H),4.60-4.40(m,2H),3.76-3.58(m,4H),3.58-3.48(m,1H),3.20-3.10(m,2H),3.08-2.97(m,2H),2.80-2.72(m,2H),2.45-2.30(m,3H),2.25-2.13(m,2H),2.13-2.04(m,2H),2.03-1.94(m,2H),1.91-1.78(m,2H),1.52-1.39(m,3H),1.34-1.12(m,4H),0.91-0.79(m,3H),0.53-0.34(m,4H)。
三、ADC的制备
实施例3-1 ADC-1
Figure PCTCN2021073279-appb-000041
在37℃条件下，向抗体PD3的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，4.0mL，270nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，67.5μL，675nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物9-A(2.9mg，2700nmol)溶解于180μL DMSO中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到如式PD3-9-A所示的示例性产物ADC-1的PBS缓冲液(1.93mg/mL，18.4mL)，于4℃储存。
UV-Vis计算平均值：n＝3.77。
实施例3-2 ADC-2
在37℃条件下，向抗体PD3的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，4.0mL，270nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，143.1μL，1431nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物9-A(4.35mg，4050nmol)溶解于270μL DMSO中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到式PD3-9-A所示的示例性产物ADC-2的PBS缓冲液(1.69mg/mL，17.8mL)，于4℃储存。
UV-Vis计算平均值：n＝6.59。
实施例3-3 ADC-3
Figure PCTCN2021073279-appb-000042
在37℃条件下，向抗体PD3的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，0.3mL，20.3nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，5.1μL，51nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物12h(0.194mg，203nmol，化合物的制备参照WO2017063509)溶解于20μL乙腈中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到含标题产物ADC-3的PBS缓冲液(4.3mg/mL，0.6mL)，于4℃储存。
UV-Vis计算平均值：n＝4.14。
实施例3-4 ADC-4
Figure PCTCN2021073279-appb-000043
其合成过程参照WO2015098099实施例19。
在37℃条件下，向抗体TINA的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，2.0mL，135.4nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，33.8μL，338nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物58(1.4mg，1354nmol)溶解于70μL DMSO中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到式TINA-58所示的示例性标题产物ADC-4的PBS缓冲液(1.13mg/mL，15.1mL)，于4℃储存。
UV-Vis计算平均值：n＝3.99。
实施例3-5 ADC-5
Figure PCTCN2021073279-appb-000044
在37℃条件下，向抗体PD3的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.5mL，101.4nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，25.3μL，253nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物58(1.05mg，1014nmol，参照专利“CN104755494A中第163页的实施例58)溶解于60μL DMSO中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液)，得到式PD3-58所示的示例性标题产物ADC-5的PBS缓冲液(0.82mg/mL，13.5mL)，于4℃储存。
UV-Vis计算平均值：n＝3.88。
实施例3-6 ADC-6
Figure PCTCN2021073279-appb-000045
在37℃条件下，向抗体hRS7的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.4mL，94.60nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，50.1μL，501nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物SN38(参照专利CN105407891A第59页实施例1合成，2.1mg，1419 nmol)溶解于50μL DMSO中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液)，得到式hRS7-SN38所示的示例性标题产物ADC-6的PBS缓冲液(1.03mg/mL，11.5mL)，于4℃储存。
CE-SDS计算平均值：n＝7.56。
实施例3-7 ADC-7
Figure PCTCN2021073279-appb-000046
在37℃条件下，向抗体hRS7的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，2.18mL，147.3nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，36.8μL，368nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物9-A(1.58mg，1471nmol)溶解于100μL DMSO中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液)，得到式hRS7-9-A所示的示例性标题产物ADC-7的PBS缓冲液(1.10mg/mL，16.4mL)，于4℃储存。
UV-Vis计算平均值：n＝3.72。
实施例3-8 ADC-8
Figure PCTCN2021073279-appb-000047
在37℃条件下，向抗体hRS7的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，2.18mL，147.3nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，36.8μL，368nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物58(1.52mg，1473nmol，参照专利“CN104755494A中第163页的 实施例58)溶解于100μLDMSO中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液)，得到式hRS7-58所示的示例性标题产物ADC-8的PBS缓冲液(1.02mg/mL，16.8mL)，于4℃储存。
UV-Vis计算平均值：n＝3.93。
实施例3-9 ADC-9
Figure PCTCN2021073279-appb-000048
在37℃条件下，向抗体TINA的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，0.95mL，64.2nmol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，16.0μL，160nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物9-A(0.69mg，642nmol)溶解于30μL DMSO中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液)，得到式TINA-9-A所示的示例性标题产物ADC-9的PBS缓冲液(0.99mg/mL，7.0mL)，于4℃储存。
UV-Vis计算平均值：n＝3.99。
ADC原液药物载量分析
ADC是一种抗体交联物类药物，其治疗疾病的机理是依赖抗体的靶向性将毒素分子运送到细胞中，进而将细胞杀死。药物的载量对药效起着决定性的作用。
一、UV-Vis计算方法
使用紫外法对ADC原液的药物载量进行测定。
实验方法
将装有琥珀酸钠缓冲液的比色皿分别置于参比吸收池和样品测定吸收池中后，扣除溶剂空白后，再将装有供试品溶液的比色皿置于样品测定吸收池中，测定280nm和370nm处吸光度。
结果计算
采用紫外分光光度法(使用仪器：Thermo nanodrop2000紫外分光光度计)测定ADC原液载量，其原理是在某波长下ADC原液的总吸光值等于细胞毒性药物 与单克隆抗体在该波长下吸光值的加和，即：
(1)A 280nm＝ε mab-280bC mab+ε Drug-280bC Drug
ε Drug-280：药物在280nm平均摩尔消光系数5100；
C Drug：药物的浓度；
ε mab-280：单抗原液在280nm平均摩尔消光系数214600；
C mab：单抗原液的浓度；
b：光程长度为1cm。
同理可以得到样品在370nm下的总吸光值方程：
(2)A 370nm＝ε mab-370bC mab+ε Drug-370bC Drug
ε Drug-370：药物在370nm平均摩尔消光系数19000；
C Drug：药物的浓度；
ε mab-370：单抗原液在370nm消光系数为0；
C mab：单抗原液的浓度；
b：光程长度为1cm。
由(1)和(2)方程结合单克隆抗体和药物在两个检测波长下的消光系数和浓度数据可以计算出药物的载量。
药物载量＝C Drug/C mab。
二、CE-SDS计算方法
试剂和仪器
SDS-Mw Analysis Kit：Beckman生产，货号390953，该试剂盒中包含SDS-MW凝胶分离缓冲液、SDS-MW样品缓冲液、酸性清洗液(0.1mol/L盐酸溶液)、碱性清洗液(0.1mol氢氧化钠溶液)、内标物质(10kDa)。也可采用北京博思雅生化技术研究院生产的SDS试剂盒，货号BSYK018，该试剂盒中包含CE-SDS凝胶缓冲液、CE-SDS样品缓冲液。
烷基化溶液(0.25mo碘乙酰胺溶液)：称取约0.046g碘乙酰胺，加入lmL超纯水溶解混匀，可于2-8℃避光保存7天。
毛细管电泳仪：SCIEX公司PA800plus。
毛细管：非涂层熔融石英毛细管(内径50μm)，切割至总长为30.2cm，高分辨率方法有效分离长度为20cm。
供试品溶液制备
用SDS样品缓冲液将供试品稀释至1mg/mL。取供试品溶液(1mg/mL)95μL，加入0.8mol/L碘乙酰胺水溶液5μL，涡旋混匀。取空白对照95μL，加入0.8mol/L碘乙酰胺水溶液5μL，涡旋混匀，从样品管中分别取出75μL至样品瓶中，立即进行分析。
测定方法
1)毛细管的预处理：0.1mol/L氢氧化钠溶液在60psi压力下冲洗3分钟，然 后用0.1mol/L盐酸溶液在60psi压力下冲洗2分钟，最后用纯水在70psi压力下冲洗1分钟。每次运行前应进行。
2)毛细管的预填充：SDS凝胶分离缓冲液在50psi压力下冲洗15分钟。每次运行前应进行。
样品进样：10kV反相极性电动进样，还原样品进样20秒。
分离：15kV下运行40分钟，反相极性。
样品室温度：18至25℃。
毛细管温度：18至25℃。
结果分析
基于抗体中打开的二硫键游离出的巯基都偶联上相应的药物，用Beckman软件对数据进行分析，以重链、非糖基化重链和轻链等校正峰面积分别占所有校正峰面积计算。根据公式：DAR＝[4*重链(H)峰面积+2*半抗(H-L)峰面积+4*双重链(H-H)峰面积+2*重重轻链(H-H-L)峰面积]/[重链(H)峰面积/2+半抗(H-L)峰面积/2+双重链(H-H)峰面积+重重轻链(H-H-L)峰面积+全抗峰面积]，最终计算出该ADC的加权平均值。
以下用生化测试方法验证本公开的抗体的活性
测试例1：抗体蛋白水平结合实验
用pH7.4的PBS(源培生物，B320)缓冲液将hTROP-2蛋白稀释至1μg/mL，以100μL/孔的体积加入96孔酶标板中，4℃过夜孵育。弃去液体后，每孔加入300μL用PBS稀释的5％脱脂牛奶(BD，232100)进行封闭，37℃孵育2小时。封闭结束后，弃去封闭液，并用PBST缓冲液(PH7.4PBS含0.1％tween-20)洗板3次后，每孔加入100μL梯度稀释的抗体溶液，于37℃孵育1小时。孵育结束后用PBST洗板3次，每孔加入100μL鼠抗-人IgG(H+L)(Jackson ImmunoResearch，209-035-088，1:8000稀释)，37℃孵育1小时。用PBST洗板3次后，每孔加入100μL TMB显色底物(KPL，5120-0077)，室温孵育10-15分钟，每孔加入50μL 1M H 2SO 4终止反应，用酶标仪读取在450nm处的吸收值，用软件拟合出抗体与抗原的结合曲线，计算出EC 50值。抗体与蛋白的结合活性见表2。
表2.抗体蛋白水平结合活性
抗体 PD3 hRS7 TINA
Emax(OD值) 1.40 1.37 1.39
EC50(nM) 13.6 18.29 16.14
结果显示，本申请中的PD3抗体与hTROP-2蛋白具有较高的结合活性。
测试例2：抗体细胞水平结合实验
将稳转TROP-2的CHOK1细胞用FACS缓冲液(2％胎牛血清(Gibco， 10099141)pH7.4PBS(Sigma,P4417-100TAB))制备成1×10 6/mL的细胞悬液，100μL/孔加入96孔圆底板中。离心去除上清后加入50μL/孔用FACS缓冲液稀释的不同浓度待测抗体，放于4℃冰箱中避光孵育1小时。以FACS缓冲液300g离心洗涤3次后，加入工作浓度的Alexa Fluor 488羊抗-人IgG(H+L)(invitrogen,A-11013)，放于4℃冰箱中避光孵育40分钟。以FACS缓冲液300g离心洗涤3次后，在BD FACSCantoII流式细胞仪上检测几何平均数荧光强度(MFI)，计算抗体对稳转表达TROP-2的细胞的结合EC 50值。抗体与细胞的结合活性见图1与表3。
表3.抗体细胞水平结合活性
抗体 PD3 hRS7 TINA
Emax(MFI) 16693 16050 14217
EC 50(nM) 1.57 2.31 3.55
结果显示，本申请中的PD3抗体与表达TROP-2蛋白的细胞具有较高的结合活性。
测试例3：抗体内吞实验
本实验的目的是根据DT3C蛋白进入细胞后，活化的DT对细胞进行杀伤，间接反映了抗TROP-2抗体的内吞情况。根据EC 50和Emax来评价抗体的体外内吞活性。
DT3C是重组表达的融合蛋白，由白喉毒素的片段A(仅毒素部分)和G群链球菌的3C片段(IgG结合部分)融合而成，该蛋白能够与抗体的IgG部分高度亲和，在抗体发生内吞时一同进入细胞，在胞内弗林蛋白酶的作用下，释放出具有毒性的DT，DT能够抑制EF2-ADP核糖基化的活性，阻断蛋白翻译过程，最终导致细胞死亡。而未进入细胞的DT3C则不具有杀伤细胞的活性。根据细胞杀伤情况来评价抗体的内吞活性。
用含20％低IgG FBS的新鲜细胞培养基制备细胞悬液，细胞密度为2×10 4细胞/mL，以50μL/孔加入细胞培养板中，5％二氧化碳37℃培养16小时。用无血清培养基配制4×浓度的DT3C，0.22μm小滤器过滤成无菌溶液。用无血清培养基配制4×浓度的抗体，将80μL DT3C和80μL抗体按照1:1的体积混匀，室温下静置孵育30分钟。取50μL稀释好的抗体-DT3C混合物加入50μL的细胞中，培养箱中孵育三天。每孔加入50μL CTG，室温下避光孵育10分钟，Victor3上读取化学发光。抗体的内吞活性见表4。
表4.抗体内吞活性
抗体 PD3 hRS7 TINA
Emax 99.1％ 98.5％ 98.7％
EC50(nM) 0.15 0.18 0.18
结果显示，本申请中的PD3抗体有较高的内吞效率。
测试例4：抗体亲和力测定
抗体对TROP-2亲和力的检测，采用捕获抗体的形式。用偶联有抗-人IgG抗体(Cat.#BR-1008-39,Lot.#10260416,GE)的Protein A(Cat.#29127556,GE)生物传感芯片亲和捕获抗体，然后于芯片表面流经抗原hTROP-2，用Biacore T200仪器实时检测反应信号获得结合和解离曲线。在每个实验循环解离完成后，用再生缓冲液Glycine1.5(Cat#BR100354，GE)或3M MgCl 2(来自Human antibody capture kit，Cat.#BR100839,GE)将芯片洗净再生。实验结束后用GE Biacore T200Evaluation version 3.0软件以(1:1)Langmuir模型拟合数据，得出亲和力数值。抗体与蛋白的亲和力见表5。
表5.Biacore测定的抗体的亲和力
抗体 PD3 hRS7 TINA
KD(M) 6.86E-10 9.87E-10 2.15E-8
结果显示，本申请中的PD3抗体与hTROP-2的亲和力较高。
测试例5：ADC分子细胞活性实验
该实验中使用的细胞如下：FaDu(++++)购于ATCC，货号HTB-43 TM；HCC827(+++)，购于ATCC，货号CRL-2868；Colo205(++)，购于中科院细胞库，货号：TCHu102；DMS53(++)，购于ATCC，货号：CRL-2062 TM；SK-OV-3(+)，购于ATCC，货号：HTB-77；CHO-K1(-)，购于ATCC，货号：CCL-61 TM。其中“+”表示细胞汇总TROP-2的表达量，“+”越多，表示TROP-2的表达量越高，“-”表示不表达TROP-2。
用含10％FBS的新鲜细胞培养基制取细胞悬液，密度为3703细胞/mL，以每孔135μL加入到96孔细胞培养板中，5％二氧化碳37℃16小时培养。ADC样品用PBS配制成5μM。以此为首浓度，用PBS五倍稀释，共8个浓度。每孔加入15μL的上述ADC溶液。5％二氧化碳37℃培养6天。每孔加入70μL CTG，室温下避光孵育10分钟，Victor3上读取化学发光利用GraphPad Prism软件进行数据分析。
结果显示ADC-1有较强的细胞杀伤效果，而且杀伤效果与肿瘤细胞表面TROP-2表达水平正向相关。
表6-1.ADC对不同TROP-2表达量细胞的杀伤活性
Figure PCTCN2021073279-appb-000049
按照上述方法进行第二次平行比较实验，获得如下结果：
表6-2.ADC对不同TROP-2表达量细胞的杀伤活性
Figure PCTCN2021073279-appb-000050
测试例6：旁观杀伤活性实验
BxPC3(人胰腺癌细胞，ATCC，CRL-1687)和MiaPaCa2细胞(人胰腺癌细胞，biocytogen，B-HCL-014)分别用RPMI1640+10％FBS和DMEM/高葡萄糖+10％FBS培养，细胞用胰酶消化，新鲜培养基中和，1000rpm离心3分钟,弃上清，细胞用RPMI1640+10％FBS重悬。细胞计数后，将BxPC3细胞密度调整为6×10 4个/mL，将MiaPaCa2-luc细胞密度调整为1.5×10 4个/mL。12孔板板1中每孔加入500μL的BxPC3细胞和500μL的MiaPaCa2-luc细胞。12孔板板2中加入500μL的MiaPaCa2-luc细胞和500μL的含10％FBS血清的RPMI1640培养液。5％二氧化碳37℃培养24小时。
ADC样品配制成40×浓度的中间溶液(0.2μM)。各取25μL上述样品加入到12孔板相应孔中。设置溶剂对照组。5％二氧化碳37℃培养6天。12孔板中的细胞用胰酶消化，新鲜培养基中和，1000rpm离心3分钟,弃上清，用1mL的FACS缓冲液(PBS+2.5％FBS)重悬，取20μL的细胞加入20μL的台盼蓝，计数。板1的细胞，1000rpm离心3分钟，弃上清，用100μL的FACS Buffer重悬，加入2μL的TROP-2(EGP-1)单克隆抗体(MR54)，冰上孵育30分钟。4℃，2000rpm离心1分钟，弃去上清，加入150μL FACS缓冲液重悬细胞。用BD FACSVerse检测。用Flowjo 7.6分析数据。旁观杀伤活性实验结果见图2。
结果显示，本公开中的ADC-1有明确的旁观杀伤效果，ADC并不会杀伤TROP-2阴性的MiaPaCa2细胞，但将表达TROP-2的BxPC3细胞与阴性细胞MiaPaCa2混合后，ADC-1对TROP-2阴性的细胞也有杀伤作用。
体内活性生物学评价
测试例7：Fadu细胞CDX小鼠模型体内药效评价
将Fadu细胞(3×10 6个)接种于Balb/c裸鼠右肋部皮下，接种10天后，待肿瘤体积在～245mm 3后去除体重、肿瘤过大和过小的，按肿瘤体积将小鼠随机分为5组，每组8只。
ADC腹腔注射，于0天和第8天共给药2次，每只按体重注射10g/0.1mL，给药量1mg/kg。每周测量2次瘤体积和体重，记录数据，共记录21天。
使用Excel统计软件记录数据：平均值以avg计算；SD值以STDEV计算；SEM值以STDEV/SQRT(每组动物数)计算；采用GraphPad Prism软件作图，采 用Two-way ANOVA或One-way ANOVA对数据进行统计学分析。
肿瘤体积(V)计算公式为：V＝1/2×L 长×L 短 2
相对肿瘤增殖率T/C(％)＝(T-T 0)/(C-C 0)×100，其中T、C为实验结束时治疗组和对照组的肿瘤体积；T 0、C 0为实验开始时的肿瘤体积。
抑瘤率TGI(％)＝1-T/C(％)。
结果见表7和图3，表明在1mpk剂量下，ADC-1对FaDu移植瘤有较强的抑瘤效果。
表7.ADC对荷瘤裸鼠FaDu移植瘤的疗效
Figure PCTCN2021073279-appb-000051
测试例8：SKOV3细胞CDX小鼠模型体内药效评价
将SKOV3细胞(5×10 6个)接种于Balb/c裸鼠右肋部皮下，接种23天后，待肿瘤体积在约180mm 3后去除体重、肿瘤过大和过小的，按肿瘤体积将小鼠随机分为5组，每组8只。
ADC腹腔注射，共给药2次，每只按体重注射10g/0.1mL，给药量见下表。每周测量2次瘤体积和体重，记录数据。使用Excel统计软件记录数据：平均值以avg计算；SD值以STDEV计算；SEM值以STDEV/SQRT(每组动物数)计算；采用GraphPad Prism软件作图，采用双因素ANOVA或单因素ANOVA对数据进行统计学分析。
肿瘤体积(V)计算公式为：V＝1/2×L 长×L 短 2
相对肿瘤增殖率T/C(％)＝(T-T 0)/(C-C 0)×100，其中T、C为实验结束时治疗组和对照组的肿瘤体积；T 0、C 0为实验开始时的肿瘤体积。
抑瘤率TGI(％)＝1-T/C(％)。
结果显示见表8和图4，在不同剂量下，ADC-1对SKOV3移植瘤有较强的抑瘤效果，同时抑瘤效果有剂量依赖效应。
效果有剂量依赖效应。
表8.ADC对荷瘤裸鼠SKOV3移植瘤的疗效
Figure PCTCN2021073279-appb-000052
Figure PCTCN2021073279-appb-000053
测试例9：Colo205细胞CDX小鼠模型体内药效评价
将Colo205细胞(5×10 6个)接种于Balb/c裸鼠右肋部皮下，接种10天后，待肿瘤体积在～245mm 3后去除体重、肿瘤过大和过小的，按肿瘤体积将小鼠随机分为6组，每组8只。
ADC腹腔注射，于第0天(D0)和第10天共给药2次，每只按体重注射10g/0.1mL，给药量10mg/kg。每周测量2次瘤体积和体重，记录数据，共记录28天(D28)。
使用Excel统计软件记录数据：平均值以avg计算；SD值以STDEV计算；SEM值以STDEV/SQRT(每组动物数)计算；采用GraphPad Prism软件作图，采用双因素ANOVA单因素ANOVA对数据进行统计学分析。
肿瘤体积(V)计算公式为：V＝1/2×L 长×L 短 2
相对肿瘤增殖率T/C(％)＝(T-T 0)/(C-C 0)×100，其中T、C为实验结束时治疗组和对照组的肿瘤体积；T 0、C 0为实验开始时的肿瘤体积。
抑瘤率TGI(％)＝1-T/C(％)。
结果见表9和图5，表明在1mpk剂量下，偶联有化合物9-A的ADC-9和ADC-7对Colo205移植瘤有较强的抑瘤效果。
表9.ADC对荷瘤裸鼠FaDu移植瘤的疗效
Figure PCTCN2021073279-appb-000054

Claims (32)

  1. 一种通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐：
    Figure PCTCN2021073279-appb-100001
    其中：
    Y选自-O-(CR aR b) m-CR 1R 2-C(O)-、-O-CR 1R 2-(CR aR b) m-、-O-CR 1R 2-、-NH-(CR aR b) m-CR 1R 2-C(O)-和-S-(CR aR b) m-CR 1R 2-C(O)-；
    R a和R b相同或不同，且各自独立地选自氢原子、氘原子、卤素、烷基、卤代烷基、氘代烷基、烷氧基、羟基、氨基、氰基、硝基、羟烷基、环烷基和杂环基；或者，R a和R b与其相连接的碳原子一起形成环烷基或杂环基；
    R 1选自卤素、卤代烷基、氘代烷基、环烷基、环烷基烷基、烷氧基烷基、杂环基、芳基和杂芳基；R 2选自氢原子、卤素、卤代烷基、氘代烷基、环烷基、环烷基烷基、烷氧基烷基、杂环基、芳基和杂芳基；或者，R 1和R 2与其相连接的碳原子一起形成环烷基或杂环基；
    或者，R a和R 2与其相连的碳原子一起形成环烷基或杂环基；
    m为0至4的整数；
    n为1至10，n是小数或整数；
    L为接头单元；
    Pc为抗TROP-2抗体或其抗原结合片段。
  2. 根据权利要求1所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含重链可变区和轻链可变区，其中所述重链可变区包含与如SEQ ID NO：3所示的重链可变区相同序列的HCDR1、HCDR2和HCDR3，所述轻链可变区包含与如SEQ ID NO：4所示的轻链可变区相同序列的LCDR1、LCDR2和LCDR3。
  3. 根据权利要求1或2所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含重链可变区和轻链可变区，其中所述重链可变区包含分别如SEQ ID NO：5、SEQ ID NO：6和 SEQ ID NO：7所示的HCDR1、HCDR2和HCDR3，所述轻链可变区包含分别如SEQ ID NO：8、SEQ ID NO：9和SEQ ID NO：10所示的LCDR1、LCDR2和LCDR3。
  4. 根据权利要求1至3中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体是鼠源抗体、嵌合抗体、人源化抗体或人抗体。
  5. 根据权利要求1至4中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含重链可变区和轻链可变区，其中：所述重链可变区的氨基酸序列如SEQ ID NO:3所示或与其有至少90％同一性，和/或所述轻链可变区的氨基酸序列如SEQ ID NO:4所示或与其有至少90％同一性。
  6. 根据权利要求1至5中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含如SEQ ID NO：3所示的重链可变区和如SEQ ID NO：4所示的轻链可变区。
  7. 根据权利要求1至6中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体或其抗原结合片段包含抗体重链恒定区和轻链恒定区；优选地，所述重链恒定区选自人IgG1、IgG2、IgG3和IgG4的恒定区，所述轻链恒定区选自人抗体κ和λ链的恒定区；更优选地，所述抗TROP-2抗体包含如SEQ ID NO：11所示的重链恒定区和如SEQ ID NO：12所示的轻链恒定区。
  8. 根据权利要求1至7中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中所述抗TROP-2抗体包含如SEQ ID NO：13所示的重链和如SEQ ID NO：14所示的轻链。
  9. 根据权利要求1至8中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中n为2至10，优选为4至8，n是小数或整数。
  10. 根据权利要求1至9中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，
    其中：
    Y为-O-(CR aR b) m-CR 1R 2-C(O)-；
    R a和R b相同或不同，且各自独立地选自氢原子、氘原子、卤素和烷基；
    R 1为卤代烷基或C 3-6环烷基；
    R 2选自氢原子、卤代烷基和C 3-6环烷基；
    或者，R 1和R 2与其相连接的碳原子一起形成C 3-6环烷基；
    m为0或1。
  11. 根据权利要求1至10中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中Y选自：
    Figure PCTCN2021073279-appb-100002
    其中Y的O端与接头单元-L-相连。
  12. 根据权利要求1至11中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中接头单元-L-为-L 1-L 2-L 3-L 4-，
    L 1选自-(琥珀酰亚胺-3-基-N)-W-C(O)-、-CH 2-C(O)-NR 3-W-C(O)-和-C(O)-W-C(O)-，其中W选自C 1-8烷基、C 1-8烷基-环烷基和1至8个链原子的直链杂烷基，所述杂烷基包含1至3个选自N、O和S的杂原子，其中所述的C 1-8烷基、环烷基和直链杂烷基各自独立地任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基的一个或多个取代基所取代；
    L 2选自-NR 4(CH 2CH 2O)pCH 2CH 2C(O)-、-NR 4(CH 2CH 2O)pCH 2C(O)-、-S(CH 2)pC(O)-和化学键，其中p为1至20的整数；
    L 3为由2至7个氨基酸残基构成的肽残基，其中所述的氨基酸残基选自苯丙氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、谷氨酸和天冬氨酸中的氨基酸形成的氨基酸残基，并任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基中的一个或多个取代基所取代；
    L 4选自-NR 5(CR 6R 7) t-、-C(O)NR 5、-C(O)NR 5(CH 2) t-和化学键，其中t为1至6的整数；
    R 3、R 4和R 5相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、氘代烷基和羟烷基；
    R 6和R 7相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氘代烷基和羟烷基。
  13. 根据权利要求1至12中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中接头单元-L-为-L 1-L 2-L 3-L 4-，
    L 1为
    Figure PCTCN2021073279-appb-100003
    s 1为2至8的整数；
    L 2为化学键；
    L 3为四肽残基；优选地，L 3为GGFG的四肽残基；
    L 4为-NR 5(CR 6R 7)t-，R 5、R 6或R 7相同或不同，且各自独立地为氢原子或烷基，t为1或2；
    其中所述的L 1端与Pc相连，L 4端与Y相连。
  14. 根据权利要求1至13中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中-L-为：
    Figure PCTCN2021073279-appb-100004
  15. 根据权利要求1至14中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其中-L-Y-任选自：
    Figure PCTCN2021073279-appb-100005
  16. 根据权利要求1至12中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其为通式(Pc-L a-Y-D)所示的配体-药物偶联物或其药学上可接受的盐：
    Figure PCTCN2021073279-appb-100006
    其中，Pc、n、m、W、L 2、L 3、R 1、R 2、R 5、R 6和R 7如权利要求1-12中任一项所定义。
  17. 根据权利要求1至13、16中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，其为通式(Pc-L b-Y-D)所示的配体-药物偶联物或其药学上可接受的盐：
    Figure PCTCN2021073279-appb-100007
    其中：
    s 1为2至8的整数；
    Pc、R 1、R 2、R 5～R 7、m和n如权利要求1-13中任一项所定义。
  18. 根据权利要求1至17中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，所述配体-药物偶联物选自：
    Figure PCTCN2021073279-appb-100008
    Figure PCTCN2021073279-appb-100009
    其中Pc和n如权利要求1至17中任一项中所定义。
  19. 根据权利要求1至18中任一项所述的通式(Pc-L-Y-D)所示的配体-药物偶联物或其药学上可接受的盐，所述配体-药物偶联物是：
    Figure PCTCN2021073279-appb-100010
    其中：
    n为1至8，n是小数或整数，优选4-8的整数或小数，更优选4-6的整数或小数；
    Pc为抗TROP-2抗体，其包含如SEQ ID NO:13所示的重链和如SEQ ID NO：14所示的轻链。
  20. 一种抗TROP-2抗体或其抗原结合片段，其包含重链可变区和轻链可变区，其中所述重链可变区包含与如SEQ ID NO：3所示的重链可变区相同序列的 HCDR1、HCDR2和HCDR3，所述轻链可变区包含与如SEQ ID NO：4所示的轻链可变区相同序列的LCDR1、LCDR2和LCDR3。
  21. 根据权利要求20所述的抗TROP-2抗体或其抗原结合片段，其包含重链可变区和轻链可变区，其中：所述重链可变区包含分别如SEQ ID NO：5、SEQ ID NO：6和SEQ ID NO：7所示的HCDR1、HCDR2和HCDR3，所述轻链可变区包含分别如SEQ ID NO：8、SEQ ID NO：9和SEQ ID NO：10所示的LCDR1、LCDR2和LCDR3。
  22. 根据权利要求20或21所述的抗TROP-2抗体或其抗原结合片段，其中所述抗TROP-2抗体是鼠源抗体、嵌合抗体、人源化抗体或人抗体。
  23. 根据权利要求20至22中任一项所述的抗TROP-2抗体或其抗原结合片段，其包含重链可变区和轻链可变区，其中：所述重链可变区的氨基酸序列如SEQ ID NO:3所示或与其有至少90％同一性，和所述轻链可变区的氨基酸序列如SEQ ID NO:4所示或与其有至少90％同一性。
  24. 根据权利要求20至23中任一项所述的抗TROP-2抗体或其抗原结合片段，其中所述抗TROP-2抗体或其抗原结合片段包含抗体重链恒定区和轻链恒定区；优选地，所述重链恒定区选自人IgG1、IgG2、IgG3和IgG4的恒定区，所述轻链恒定区选自人抗体κ和λ链的恒定区；
    更优选地，所述抗TROP-2抗体包含如SEQ ID NO：11所示的重链恒定区和如SEQ ID NO：12所示的轻链恒定区。
  25. 根据权利要求20至24中任一项所述的抗TROP-2抗体或其抗原结合片段，其中所述抗TROP-2抗体包含如SEQ ID NO：13所示的重链和如SEQ ID NO：14所示的轻链。
  26. 一种核酸分子，其编码权利要求20至25中任一项所述的抗TROP-2抗体或其抗原结合片段。
  27. 一种宿主细胞，其包含如权利要求26所述的核酸分子。
  28. 一种制备如通式(Pc-L a-Y-D)所示的配体-药物偶联物或其药学上可接受的盐的方法，其包括以下步骤：
    Figure PCTCN2021073279-appb-100011
    Pc还原后，与通式(L a-Y-D)所示的化合物进行偶联反应，得到通式(Pc-L a-Y-D)所示的化合物；
    其中：
    Pc为抗TROP-2抗体或其抗原结合片段；优选地，Pc为权利要求20至25中任一项所述的抗TROP-2抗体或其抗原结合片段；
    n、m、W、L 2、L 3、R 1、R 2、R 5、R 6和R 7如权利要求16中所定义。
  29. 一种药物组合物，其包含：
    根据权利要求1至19中任一项所述的抗体-药物偶联物或其药学上可接受的盐，或根据权利要求20至25中任一项所述的抗TROP-2抗体或其抗原结合片段，以及
    一种或多种药学上可接受的赋形剂、稀释剂或载体。
  30. 根据权利要求1至19中任一项所述的抗体-药物偶联物或其药学上可接受的盐、根据权利要求20至25中任一项所述的抗TROP-2抗体或其抗原结合片段、或根据权利要求29所述的药物组合物在制备用于治疗TROP-2介导的疾病或病症的药物中的用途。
  31. 根据权利要求1至19中任一项所述的抗体-药物偶联物或其药学上可接受 的盐、根据权利要求20至25中任一项所述的抗TROP-2抗体或其抗原结合片段、或根据权利要求29所述的药物组合物在制备用于治疗肿瘤的药物中的用途。
  32. 根据权利要求1至19中任一项所述的抗体-药物偶联物或其药学上可接受的盐、根据权利要求20至25中任一项所述的抗TROP-2抗体或其抗原结合片段、或根据权利要求29所述的药物组合物在制备治疗和/或预防肿瘤和癌症的药物中的用途，其中所述肿瘤和癌症优选头和颈鳞状细胞癌、头和颈癌、脑癌、神经胶质瘤、多形性成胶质细胞瘤、神经母细胞瘤、中枢神经系统癌、神经内分泌肿瘤、咽喉癌、咽鳞癌、口腔鳞癌、鼻咽癌、食管癌、甲状腺癌、恶性胸膜间皮瘤、肺癌、乳腺癌、肝癌、肝胆癌、胰腺癌、胃癌、胃肠道癌、肠癌、结肠癌、结肠直肠癌、肾癌、透明细胞肾细胞癌、卵巢癌、子宫内膜癌、子宫颈癌、膀胱癌、前列腺癌、睾丸癌、皮肤癌、黑色素瘤、白血病、淋巴瘤、骨癌、软骨肉瘤、骨髓瘤、多发性骨髓瘤、骨髓异常增生综合征、库肯勃氏瘤、骨髓增生性肿瘤、鳞状细胞癌、尤因氏肉瘤、尿路上皮癌和梅克尔细胞癌；更优选的，所述淋巴瘤选自：何杰金淋巴瘤、非何杰金淋巴瘤、弥漫性大B-细胞淋巴瘤、滤泡性淋巴瘤、原发性纵隔大B-细胞淋巴瘤、套细胞淋巴瘤、小淋巴细胞性淋巴瘤、富含T-细胞/组织细胞的大B-细胞淋巴瘤和淋巴浆细胞性淋巴瘤；所述肺癌选自：非小细胞肺癌和小细胞肺癌；所述白血病选自：慢性髓细胞样白血病、急性髓细胞样白血病、淋巴细胞白血病、成淋巴细胞性白血病、急性成淋巴细胞性白血病、慢性淋巴细胞性白血病和髓样细胞白血病。
PCT/CN2021/073279 2020-01-22 2021-01-22 抗trop-2抗体-依喜替康类似物偶联物及其医药用途 WO2021147993A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2021210074A AU2021210074A1 (en) 2020-01-22 2021-01-22 Anti-TROP-2 antibody-exatecan analog conjugate and medical use thereof
EP21744789.5A EP4095148A4 (en) 2020-01-22 2021-01-22 ANTI-TROP-2 ANTIBODY EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF
CN202180007477.0A CN114846021A (zh) 2020-01-22 2021-01-22 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
KR1020227026893A KR20220130717A (ko) 2020-01-22 2021-01-22 항-trop-2 항체-엑사테칸 유사체 접합체 및 이의 의학적 용도
JP2022543188A JP2023510905A (ja) 2020-01-22 2021-01-22 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途
CA3168260A CA3168260A1 (en) 2020-01-22 2021-01-22 Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
MX2022008474A MX2022008474A (es) 2020-01-22 2021-01-22 Conjugado de anticuerpo anti-trop-2-analogo de exatecan y uso medico del mismo.
US17/793,005 US20230101735A1 (en) 2020-01-22 2021-01-22 Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
BR112022014189A BR112022014189A2 (pt) 2020-01-22 2021-01-22 Conjugado de anticorpo anti-trop-2 análogo de exatecano e uso médico do mesmo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010073438 2020-01-22
CN202010073438.8 2020-01-22

Publications (1)

Publication Number Publication Date
WO2021147993A1 true WO2021147993A1 (zh) 2021-07-29

Family

ID=76992053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/073279 WO2021147993A1 (zh) 2020-01-22 2021-01-22 抗trop-2抗体-依喜替康类似物偶联物及其医药用途

Country Status (11)

Country Link
US (1) US20230101735A1 (zh)
EP (1) EP4095148A4 (zh)
JP (1) JP2023510905A (zh)
KR (1) KR20220130717A (zh)
CN (1) CN114846021A (zh)
AU (1) AU2021210074A1 (zh)
BR (1) BR112022014189A2 (zh)
CA (1) CA3168260A1 (zh)
MX (1) MX2022008474A (zh)
TW (1) TW202140077A (zh)
WO (1) WO2021147993A1 (zh)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022078259A1 (zh) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
WO2022166762A1 (zh) * 2021-02-05 2022-08-11 四川科伦博泰生物医药股份有限公司 喜树碱类化合物及其制备方法和应用
WO2022253284A1 (zh) 2021-06-02 2022-12-08 百奥泰生物制药股份有限公司 药物偶联物及其用途
WO2023001248A1 (zh) * 2021-07-21 2023-01-26 江苏恒瑞医药股份有限公司 一种含抗trop2抗体药物偶联物的药物组合物及其用途
WO2023088382A1 (zh) * 2021-11-17 2023-05-25 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
WO2023098889A1 (zh) * 2021-12-03 2023-06-08 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
WO2023201268A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating tumor antigen expressing cancers
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023214849A1 (ko) * 2022-05-04 2023-11-09 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신계 약물이 산 민감성 링커에 연결된 접합체 및 이를 이용한 면역접합체
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
WO2023237050A1 (en) * 2022-06-09 2023-12-14 Beigene, Ltd. Antibody drug conjugates

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0737686A1 (en) 1995-04-10 1996-10-16 Daiichi Pharmaceutical Co., Ltd. Camthothecin derivative with antitumour activity
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
US20050020645A1 (en) 2001-06-20 2005-01-27 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2013096771A1 (en) 2011-12-21 2013-06-27 Ardelyx, Inc. Non-systemic tgr5 agonists
WO2013106717A1 (en) 2012-01-13 2013-07-18 The General Hospital Corporation Anesthetic compounds and related methods of use
WO2015047510A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
CN104755494A (zh) 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
WO2015098099A1 (ja) 2013-12-25 2015-07-02 第一三共株式会社 抗ｔｒｏｐ２抗体－薬物コンジュゲート
CN105407891A (zh) 2013-07-23 2016-03-16 免疫医疗公司 具有cl2a接头的抗体-sn-38免疫缀合物
CN105829346A (zh) 2014-01-31 2016-08-03 第三共株式会社 抗her2抗体－药物偶联物
WO2017063509A1 (zh) 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用
WO2019114666A1 (zh) * 2017-12-15 2019-06-20 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN110526978A (zh) * 2017-08-11 2019-12-03 百奥泰生物制药股份有限公司 Trop2阳性疾病治疗的化合物及方法

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0737686A1 (en) 1995-04-10 1996-10-16 Daiichi Pharmaceutical Co., Ltd. Camthothecin derivative with antitumour activity
US20050020645A1 (en) 2001-06-20 2005-01-27 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2013096771A1 (en) 2011-12-21 2013-06-27 Ardelyx, Inc. Non-systemic tgr5 agonists
WO2013106717A1 (en) 2012-01-13 2013-07-18 The General Hospital Corporation Anesthetic compounds and related methods of use
CN104755494A (zh) 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
EP2907824A1 (en) 2012-10-11 2015-08-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate
CN105407891A (zh) 2013-07-23 2016-03-16 免疫医疗公司 具有cl2a接头的抗体-sn-38免疫缀合物
WO2015047510A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
WO2015098099A1 (ja) 2013-12-25 2015-07-02 第一三共株式会社 抗ｔｒｏｐ２抗体－薬物コンジュゲート
CN105829346A (zh) 2014-01-31 2016-08-03 第三共株式会社 抗her2抗体－药物偶联物
WO2017063509A1 (zh) 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用
CN110526978A (zh) * 2017-08-11 2019-12-03 百奥泰生物制药股份有限公司 Trop2阳性疾病治疗的化合物及方法
WO2019114666A1 (zh) * 2017-12-15 2019-06-20 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Epitope Mapping Protocols in Methods in Molecular B iology", vol. 66, 1996
ALFTHAN ET AL., PROTEIN ENG, vol. 8, 1995, pages 725 - 731
AL-LAZIKANI, JMB, vol. 273, 1997, pages 927 - 948
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
CHARI ET AL., CANCER RESEARCH, vol. 52, 1992, pages 127 - 131
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, pages 94 - 106
DAVID M GOLDENBERG, CARDILLO THOMAS M, GOVINDAN SERENGULAM V, ROSSI EDMUND A, SHARKEY ROBERT M: "Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)", ONCOTARGET, vol. 6, no. 26, 18 June 2015 (2015-06-18), pages 22496 - 22512, XP055269616, DOI: 10.18632/oncotarget.4318 *
HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
HUSTON ET AL., PROC. NATL. ACAD. SCI USA, vol. 85, 1988, pages 5879 - 5883
J. BIOL. CHEM, vol. 243, 1968, pages 3558
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 136, no. 22, 2014, pages 8138 - 8142
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
LEFRANC M.P., IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LEFRANC, G.: "Antibodies: A Laboratory Manual", 2001, COLD SPRING HARBOR PRESS
LEFRANC, M.P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
ROOVERS ET AL., CANCER IMMUNOL, 2001
T. M. CARDILLO, S. V. GOVINDAN, R. M. SHARKEY, P. TRISAL, D. M. GOLDENBERG: "Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 17, no. 10, 15 May 2011 (2011-05-15), US, pages 3157 - 3169, XP055398728, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2939 *
TETRAHEDRON LETTERS, vol. 25, no. 12, 1984, pages 1269 - 72
THOMAS M. CARDILLO, SERENGULAM V. GOVINDAN, ROBERT M. SHARKEY, PREETI TRISAL, ROBERTO ARROJO, DONGLIN LIU, EDMUND A. ROSSI, CHIEN-: "Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 26, no. 5, 20 May 2015 (2015-05-20), US, pages 919 - 931, XP055268276, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00223 *
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022078259A1 (zh) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
WO2022166762A1 (zh) * 2021-02-05 2022-08-11 四川科伦博泰生物医药股份有限公司 喜树碱类化合物及其制备方法和应用
WO2022253284A1 (zh) 2021-06-02 2022-12-08 百奥泰生物制药股份有限公司 药物偶联物及其用途
WO2023001248A1 (zh) * 2021-07-21 2023-01-26 江苏恒瑞医药股份有限公司 一种含抗trop2抗体药物偶联物的药物组合物及其用途
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
WO2023088382A1 (zh) * 2021-11-17 2023-05-25 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
WO2023098889A1 (zh) * 2021-12-03 2023-06-08 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
WO2023201268A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating tumor antigen expressing cancers
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023214849A1 (ko) * 2022-05-04 2023-11-09 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신계 약물이 산 민감성 링커에 연결된 접합체 및 이를 이용한 면역접합체
WO2023237050A1 (en) * 2022-06-09 2023-12-14 Beigene, Ltd. Antibody drug conjugates

Also Published As

Publication number Publication date
AU2021210074A1 (en) 2022-07-28
TW202140077A (zh) 2021-11-01
EP4095148A4 (en) 2023-07-26
JP2023510905A (ja) 2023-03-15
KR20220130717A (ko) 2022-09-27
CA3168260A1 (en) 2021-07-29
BR112022014189A2 (pt) 2022-11-29
US20230101735A1 (en) 2023-03-30
EP4095148A1 (en) 2022-11-30
CN114846021A (zh) 2022-08-02
MX2022008474A (es) 2022-08-02

Similar Documents

Publication Publication Date Title
WO2021147993A1 (zh) 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
WO2020063673A1 (zh) 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
WO2021148003A1 (zh) 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
WO2021115426A1 (zh) 抗密蛋白抗体药物偶联物及其医药用途
WO2021190586A1 (zh) B7h3抗体-依喜替康类似物偶联物及其医药用途
WO2022022508A1 (zh) 抗cd79b抗体药物偶联物、其制备方法及其医药用途
WO2021058027A1 (zh) 吡咯并杂芳基衍生物或其偶联物、其制备方法及其应用
CN113121639A (zh) 澳瑞他汀类似物及其偶联物、其制备方法及其应用
WO2021121204A1 (zh) 抗cea抗体-依喜替康类似物偶联物及其医药用途
WO2021190583A1 (zh) 抗psma抗体-依喜替康类似物偶联物及其医药用途
WO2023001300A1 (zh) 艾日布林衍生物的药物偶联物
RU2785664C2 (ru) Конъюгат антитело к b7h3-аналог экзатекана и его применение в медицине

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21744789

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022543188

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3168260

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022014189

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2021210074

Country of ref document: AU

Date of ref document: 20210122

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227026893

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022118238

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021744789

Country of ref document: EP

Effective date: 20220822

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112022014189

Country of ref document: BR

Free format text: APRESENTE NOVO CONTEUDO ELETRONICO DE LISTAGEM DE SEQUENCIAS BIOLOGICAS, UMA VEZ QUE O APRESENTADO NA PETICAO NO 870220063304 POSSUI DADOS DIVERGENTES NOS CAMPOS 110 (DEPOSITANTE) E 120 (TITULO).

ENP Entry into the national phase

Ref document number: 112022014189

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220719